

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
18 May 2017 (18.05.2017)



(10) International Publication Number
WO 2017/083776 A9

(51) International Patent Classification:

A61K 48/00 (2006.01) *A61P 39/06* (2006.01)
A61P 21/00 (2006.01) *C07K 14/435* (2006.01)

(21) International Application Number:

PCT/US2016/061703

(22) International Filing Date:

11 November 2016 (11.11.2016)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/254,539 12 November 2015 (12.11.2015) US
62/419,793 09 November 2016 (09.11.2016) US

(71) Applicant: RESEARCH INSTITUTE AT NATION-
WIDE CHILDREN'S HOSPITAL [US/US]; 700
Children's Drive, Room W 172, Columbus, OH 43205 (US).


(72) Inventor: RODINO-KLAPAC, Louise; 4912 Bixby
Ridge Drive, E. Groveport, OH 43125 (US).

(74) Agent: SINTICH, Sharon, M.; Marshall, Gerstein &
Borun LLP, 233 S. Wacker Drive, 6300 Willis Tower,
Chicago, IL 60606-6357 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW,
KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK,
MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA,
PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD,
SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: METHODS OF TREATING MUSCULAR DYSTROPHY



(57) Abstract: The invention provides for AAV vectors expressing the ANO5 gene and antioxidant therapy as methods of inducing muscle regeneration and a method of treating muscular dystrophy.

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

(48) Date of publication of this corrected version:

31 May 2018 (31.05.2018)

(15) Information about Correction:

see Notice of 31 May 2018 (31.05.2018)

METHODS OF TREATING MUSCULAR DYSTROPHY

[0001] This application claims priority to US Provisional Patent Application No. 62/254539, filed on November 12, 2015 and US Provisional Patent Application No. 62/419793, filed November 9, 2016, which are incorporated by reference herein in
5 their entirety.

FIELD OF INVENTION

[0002] The invention provides for AAV vectors expressing the ANO5 gene and antioxidant therapy as methods of inducing muscle regeneration and a method of treating muscular dystrophy.

10

BACKGROUND

[0003] The importance of muscle mass and strength for daily activities such as locomotion and breathing and for whole body metabolism is unequivocal. Deficits in muscle function produce muscular dystrophies (MDs) that are characterized by muscle weakness and wasting and have serious impacts on quality of life. The most
15 well-characterized MDs result from mutations in genes encoding members of the dystrophin-associated protein complex (DAPC). These MDs result from membrane fragility associated with the loss of sarcolemmal-cytoskeleton tethering by the DAPC. In contrast, a subset of other MDs is thought to be caused by defects in sarcolemmal repair. Owing to the mechanical stress the sarcolemma experiences during
20 contraction, even healthy muscle is in constant need of repair mechanisms to patch injured membrane. Sarcolemmal patch repair relies on the fusion of membrane vesicles at sites of damage, and the attenuation of this process is putatively considered a major cause of dysferlinopathies, MDs caused by mutations in dysferlin.

[0004] Recently, a new MD with features similar to dysferlinopathies and
25 characterized by sarcolemmal lesions has been linked to recessive mutations in ANO5 (TMEM16E). ANO5 mutations produce limb-girdle muscular dystrophy type 2L (LGMD2L) and Miyoshi myopathy dystrophy type 3 (MMD3). The phenotype associated with ANO5 mutations is variable, but typically the disease presents in adulthood (age 20 to 50) with proximal lower limb weakness, high serum creatine
30 kinase levels, asymmetric muscle atrophy and weakness and is typically accompanied by sarcolemmal lesions, similar to dysferlinopathy (Bolduc *et al.*, *American journal of*

human genetics 86, 213-221 (2010)), Hicks *et al.*, *Brain : a journal of neurology* 134, 171-182 (2011), Bouquet *et al.*, *Revue neurologique* 168, 135-141 (2012)). To date, ~72 different ANO5 mutations have been reported in MD patients, and screens for ANO5 mutations in LGMD patients lacking mutations in other known LGMD genes indicate that ANO5 mutations may be one of the more common causes of LGMD (Bolduc *et al.*, *American journal of human genetics* 86, 213-221 (2010)), Hicks *et al.*, *Brain : a journal of neurology* 134, 171-182 (2011), Penttila *et al.*, *Neurology* 78, 897-903 (2012)).

[0005] The Anoctamin/TMEM16 family has been functionally split into two categories. The founding members, ANO1 (TMEM16A) and ANO2 (TMEM16B) encode calcium-activated chloride channels, while other ANOs fail to conduct chloride currents and have been identified for their roles in phospholipid scrambling (PLS). However, ANO5 has not been found to exhibit either of these two activities at suggesting a novel function in skeletal muscle,. Given this novelty, it remains unclear how the deficiency in ANO5 function elicits a LGMD phenotype, and specifically why *Ano5* mutations manifest in a clinically similar way to dysferlin-associated MD.

[0006] Adeno-associated virus (AAV) is a replication-deficient parvovirus, the single-stranded DNA genome of which is about 4.7 kb in length including 145 nucleotide inverted terminal repeat (ITRs). There are multiple serotypes of AAV. The nucleotide sequences of the genomes of the AAV serotypes are known. For example, the nucleotide sequence of the AAV serotype 2 (AAV2) genome is presented in Srivastava *et al.*, *J Virol*, 45: 555-564 (1983) as corrected by Ruffing *et al.*, *J Gen Virol*, 75: 3385-3392 (1994). As other examples, the complete genome of AAV-1 is provided in GenBank Accession No. NC_002077; the complete genome of AAV-3 is provided in GenBank Accession No. NC_1829; the complete genome of AAV-4 is provided in GenBank Accession No. NC_001829; the AAV-5 genome is provided in GenBank Accession No. AF085716; the complete genome of AAV-6 is provided in GenBank Accession No. NC_001862; at least portions of AAV-7 and AAV-8 genomes are provided in GenBank Accession Nos. AX753246 and AX753249, respectively (see also U.S. Patent Nos. 7,282,199 and 7,790,449 relating to AAV-8); the AAV-9 genome is provided in Gao *et al.*, *J. Virol.*, 78: 6381-6388 (2004); the AAV-10 genome is provided in *Mol. Ther.*, 13(1): 67-76 (2006); and the

AAV-11 genome is provided in *Virology*, 330(2): 375-383 (2004). The sequence of the AAV rh.74 genome is provided herein. *Cis*-acting sequences directing viral DNA replication (rep), encapsidation/packaging and host cell chromosome integration are contained within the ITRs. Three AAV promoters (named p5, p19, and p40 for their relative map locations) drive the expression of the two AAV internal open reading frames encoding rep and cap genes. The two rep promoters (p5 and p19), coupled with the differential splicing of the single AAV intron (*e.g.*, at AAV2 nucleotides 2107 and 2227), result in the production of four rep proteins (rep 78, rep 68, rep 52, and rep 40) from the rep gene. Rep proteins possess multiple enzymatic properties that are ultimately responsible for replicating the viral genome. The cap gene is expressed from the p40 promoter and it encodes the three capsid proteins VP1, VP2, and VP3. Alternative splicing and non-consensus translational start sites are responsible for the production of the three related capsid proteins. A single consensus polyadenylation site is located at map position 95 of the AAV genome. The life cycle and genetics of AAV are reviewed in Muzyczka, *Current Topics in Microbiology and Immunology*, 158: 97-129 (1992).

[0007] AAV possesses unique features that make it attractive as a vector for delivering foreign DNA to cells, for example, in gene therapy. AAV infection of cells in culture is noncytopathic, and natural infection of humans and other animals is silent and asymptomatic. Moreover, AAV infects many mammalian cells allowing the possibility of targeting many different tissues *in vivo*. Moreover, AAV transduces slowly dividing and non-dividing cells, and can persist essentially for the lifetime of those cells as a transcriptionally active nuclear episome (extrachromosomal element). The AAV proviral genome is infectious as cloned DNA in plasmids which makes construction of recombinant genomes feasible. Furthermore, because the signals directing AAV replication, genome encapsidation and integration are contained within the ITRs of the AAV genome, some or all of the internal approximately 4.3 kb of the genome (encoding replication and structural capsid proteins, rep-cap) may be replaced with foreign DNA such as a gene cassette containing a promoter, a DNA of interest and a polyadenylation signal. The rep and cap proteins may be provided *in trans*. Another significant feature of AAV is that it is an extremely stable and hearty virus. It easily withstands the conditions used to inactivate adenovirus (56° to 65°C for

several hours), making cold preservation of AAV less critical. AAV may even be lyophilized. Finally, AAV-infected cells are not resistant to superinfection.

- [0008] Multiple studies have demonstrated long-term (> 1.5 years) recombinant AAV-mediated protein expression in muscle. See, Clark *et al.*, *Hum Gene Ther*, 8: 659-669 (1997); Kessler *et al.*, *Proc Natl Acad Sci USA*, 93: 14082-14087 (1996); and Xiao *et al.*, *J Virol*, 70: 8098-8108 (1996). See also, Chao *et al.*, *Mol Ther*, 2:619-623 (2000) and Chao *et al.*, *Mol Ther*, 4:217-222 (2001). Moreover, because muscle is highly vascularized, recombinant AAV transduction has resulted in the appearance of transgene products in the systemic circulation following intramuscular injection as described in Herzog *et al.*, *Proc Natl Acad Sci USA*, 94: 5804-5809 (1997) and Murphy *et al.*, *Proc Natl Acad Sci USA*, 94: 13921-13926 (1997). Moreover, Lewis *et al.*, *J Virol*, 76: 8769-8775 (2002) demonstrated that skeletal myofibers possess the necessary cellular factors for correct antibody glycosylation, folding, and secretion, indicating that muscle is capable of stable expression of secreted protein therapeutics.
- [0009] As shown herein, disruption of the *Ano5* gene in mice produces several dystrophic muscle histopathogenic features, exercise intolerance, dysfunction in sarcolemmal repair, and myoblast fusion defects. In addition, the data provided demonstrates that these defects are related to changes in subcellular membrane and/or membrane and/or sarcolemmal membrane dynamics mediated by ANO5. The present invention relates to using AAV vectors expressing the *Ano5* gene in methods of inducing muscle repair and/or treating MD.

SUMMARY OF INVENTION

- [0010] The present invention is directed to AAV vectors comprising a nucleotide sequence encoding the ANO5 protein or a functionally active fragment thereof. The experiments described in the Examples 1-4 demonstrate an essential role for *Ano5* in muscle regeneration and repair. Loss of ANO5 causes a dystrophic phenotype in mice, reminiscent of LGMD2L patients, with mild histopathology that varies among muscles, exercise intolerance, impaired regeneration, and elevated creatine kinase levels. Mitochondrial abnormalities were observed in both young and aged *Ano5*^{-/-} mice. In addition to the structural defect of the mitochondria displayed through electron microscopic imaging, citrate synthase quantification assays also demonstrated that the mitochondria have a functional deficit. Quantitative enzyme

analysis of citrate synthase suggests the presence of damaged mitochondria. These results suggest that mitochondrial abnormalities may be a secondary effect caused by the loss of the Anoctamin 5 protein. The experiments described herein demonstrate an attenuation of sarcolemmal patch repair in *Ano5^{-/-}* fibers that is rescued by viral expression of human ANO5 and find that the disruption of Ano5 perturbs the fusogenic quality of primary myoblasts.

[0011] In one embodiment, the invention provides for a recombinant AAV vector comprising a polynucleotide comprising an ANO5 nucleic acid sequence. The ANO5 nucleic acid sequence is set out as Genbank Accession No. NM_213599.2 (SEQ ID NO: 13). An exemplary nucleic acid sequence encoding the ANO5 protein in an AAV vector is set out as SEQ ID NO: 1. The recombinant vectors of the present invention comprise a polynucleotide sequence that is at least is at least 85% identical to nucleic acid of SEQ ID NO:1 or SEQ ID NO: 13 or comprise a nucleotide that hybridizes under stringent condition to the nucleotide sequence of SEQ ID NO: 1 or SEQ ID NO: 13 or comprises a fragment of nucleic acid of SEQ ID NO: 1 or SEQ ID NO: 13 encoding a protein that exhibits ANO5 activity. In one aspect, the recombinant AAV vectors of the invention are AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13 or AAV rh.74.

[0012] The recombinant AAV vectors of the invention comprise a fragment of SEQ ID NO: 1 that encodes a protein that comprise a domain that is involved in PLS activity and said protein retains PLS activity. In another embodiment, the AAV vector comprises a fragment of SEQ ID NO: 1 or SEQ ID NO: 13 that encodes a protein that retains ANO5 activity.

[0013] The recombinant AAV vectors of the invention comprise a polynucleotide sequence that is, e.g., at least 65%, at least 70%, at least 75%, at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 89%, more typically at least 90%, 91%, 92%, 93%, or 94% and even more typically at least 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 1 or SEQ ID NO: 13, wherein the polynucleotide encodes a protein that retains ANO5 activity.

[0014] The recombinant AAV vectors of the invention comprise a polynucleotide sequence encoding a ANO5 protein that is, e.g., at least at least 65%, at least 70%, at least 75%, at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, or 89%, more

typically at least 90%, 91%, 92%, 93%, or 94% and even more typically at least 95%, 96%, 97%, 98% or 99% sequence identity to SEQ ID NO: 2, wherein the polynucleotide encodes a protein that retains ANO5 activity

5 [0015] The recombinant AAV vectors of the invention comprise a polynucleotide sequence that hybridizes under stringent conditions to the nucleic acid sequence of SEQ ID NOS: 1 or SEQ ID NO: 13, or compliments thereof, which fragment is greater than about 5 nucleotides, preferably 7 nucleotides, more preferably greater than 9 nucleotides and most preferably greater than 17 nucleotides. Fragments of, e.g., 15, 17, or 20 nucleotides or more that are selective for (i.e., specifically hybridize
10 to any one of the polynucleotides of the invention) are contemplated and these fragment retain ANO5 activity. Probes capable of specifically hybridizing to a polynucleotide can differentiate NTHi polynucleotide sequences of the invention from other polynucleotide sequences in the same family of genes or can differentiate NTHi genes from other bacterial genes, and are preferably based on unique nucleotide
15 sequences.

[0016] The term “stringent” is used to refer to conditions that are commonly understood in the art as stringent. Hybridization stringency is principally determined by temperature, ionic strength, and the concentration of denaturing agents such as formamide. Examples of stringent conditions for hybridization and washing are 0.015
20 M sodium chloride, 0.0015 M sodium citrate at 65-68°C or 0.015 M sodium chloride, 0.0015M sodium citrate, and 50% formamide at 42°C. See Sambrook *et al.*, Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory, (Cold Spring Harbor, N.Y. 1989). More stringent conditions (such as higher temperature, lower ionic strength, higher formamide, or other denaturing agent) may
25 also be used, however, the rate of hybridization will be affected. In instances wherein hybridization of deoxyoligonucleotides is concerned, additional exemplary stringent hybridization conditions include washing in 6x SSC 0.05% sodium pyrophosphate at 37°C (for 14-base oligos), 48°C (for 17-base oligos), 55°C (for 20-base oligos), and 60°C (for 23-base oligos).

30 [0017] Other agents may be included in the hybridization and washing buffers for the purpose of reducing non-specific and/or background hybridization. Examples are 0.1% bovine serum albumin, 0.1% polyvinyl-pyrrolidone, 0.1% sodium

pyrophosphate, 0.1% sodium dodecylsulfate, NaDodSO₄, (SDS), ficoll, Denhardt's solution, sonicated salmon sperm DNA (or other non-complementary DNA), and dextran sulfate, although other suitable agents can also be used. The concentration and types of these additives can be changed without substantially affecting the stringency of the hybridization conditions. Hybridization experiments are usually carried out at pH 6.8-7.4, however, at typical ionic strength conditions, the rate of hybridization is nearly independent of pH. See Anderson *et al.*, Nucleic Acid Hybridisation: A Practical Approach, Ch. 4, IRL Press Limited (Oxford, England). Hybridization conditions can be adjusted by one skilled in the art in order to accommodate these variables and allow DNAs of different sequence relatedness to form hybrids.

[0018] In another aspect, the recombinant AAV vectors of the invention may be operably linked to a muscle-specific control element. For example the muscle-specific control element is human skeletal actin gene element, cardiac actin gene element, myocyte-specific enhancer binding factor MEF, murine creatine kinase enhancer element (MCK), triple copies of the MCK (tMCK), skeletal fast-twitch troponin C gene element, slow-twitch cardiac troponin C gene element, the slow-twitch troponin I gene element, hypoxia-inducible nuclear factors, steroid-inducible element or glucocorticoid response element (GRE).

[0019] In another embodiment, the invention provides for methods of producing a recombinant AAV vector particle comprising culturing a cell that has been transfected with any recombinant AAV vector of the invention and recovering recombinant AAV particles from the supernatant of the transfected cells. The invention also provides for viral particles comprising any of the recombinant AAV vectors of the invention.

[0020] In another embodiment, the invention provides for methods of treating muscular dystrophy comprising administering a therapeutically effective amount of any recombinant AAV vector of the invention to a subject in need thereof. In one aspect, the subject in need has a recessive mutation in the ANO5 gene. The methods may treat dysferlin-associated muscular dystrophy, limb girdle muscular dystrophy type 2L, Miyoshi myopathy type 3, Bethlem myopathy, calpainopathy, desmin myopathy, dysferlinopathy, myofibrillar myopathy, sarcoglycanopathie or ZASP-related myopathy. In addition, any of the foregoing methods to treat muscular

dystrophy further comprise the step of administering a therapeutically effective amount of an antioxidant composition to a subject in need thereof. For example, the antioxidant composition comprises at least one of a coenzyme Q10, lipoic acid, vitamin, carotenoid, vitamin cofactor, mineral, polyphenol, or flavonoid. In particular, the antioxidant composition comprises coenzyme Q10, lipoic acid and vitamin E.

[0021] In a further embodiment, the invention provides for methods of regenerating muscle in a subject in need comprising administering a therapeutically effective amount of any recombinant AAV vector of the invention to subject in need thereof. In one aspect, the subject in need has a recessive mutation in the ANO5 gene. In another aspect, the subject in need is suffering from muscular dystrophy such as dysferlin-associated muscular dystrophy, limb girdle muscular dystrophy type 2L, Miyoshi myopathy type 3, Bethlem myopathy, calpainopathy, desmin myopathy, dysferlinopathy, myofibrillar myopathy, sarcoglycanopathie or ZASP-related myopathy. In addition, any of the foregoing methods to regenerate muscle further comprise the step of administering a therapeutically effective amount of an antioxidant composition to a subject in need thereof. For example, the antioxidant composition comprises at least one of a coenzyme Q10, lipoic acid, vitamin, carotenoid, vitamin cofactor, mineral, polyphenol, or flavonoid. In particular, the antioxidant composition comprises coenzyme Q10, lipoic acid and vitamin E.

[0022] In another embodiment, the invention provides for methods of treating chronic muscle wasting comprising administering a therapeutically effective amount of any of the recombinant AAV vectors of the invention to subject in need thereof. In one aspect, the subject in need has a recessive mutation in the ANO5 gene. In another aspect, the subject in need is suffering from muscular dystrophy such as dysferlin-associated muscular dystrophy, limb girdle muscular dystrophy type 2L or Miyoshi myopathy type 3, Bethlem myopathy, calpainopathy, desmin myopathy, dysferlinopathy, myofibrillar myopathy, sarcoglycanopathie or ZASP-related myopathy. In addition, any of the foregoing methods to treat chronic muscle wasting further comprise the step of administering a therapeutically effective amount of an antioxidant composition to a subject in need thereof. For example, the antioxidant composition comprises at least one of a coenzyme Q10, lipoic acid, vitamin,

carotenoid, vitamin cofactor, mineral, polyphenol, or flavonoid. In particular, the antioxidant composition comprises coenzyme Q10, lipoic acid and vitamin E.

[0023] The invention also provides for a composition comprising any recombinant AAV vector of the invention for the treatment of muscular dystrophy or chronic muscle wasting syndrome in a subject in need. The invention also provides for composition comprising any recombinant AAV vector of the invention for the regeneration of muscle in a subject in need. In one aspect, the composition of the invention is administered to a subject having recessive mutation in the ANO5 gene. In another aspect, the composition of the invention is administered to a subject in suffering from muscular dystrophy such as dysferlin-associated muscular dystrophy, limb girdle muscular dystrophy type 2L, Miyoshi myopathy type 3, Bethlem myopathy, calpainopathy, desmin myopathy, dysferlinopathy, myofibrillar myopathy, sarcoglycanopathie or ZASP-related myopathy. Any of the compositions of the invention are formulated for intramuscular or intravenous injection. Any of the compositions of the invention further comprise a therapeutically effective amount of an antioxidant composition. For example, the antioxidant composition comprises at least one of a coenzyme Q10, lipoic acid, vitamin, carotenoid, vitamin cofactor, mineral, polyphenol, or flavonoid. In particular, the antioxidant composition comprises coenzyme Q10, lipoic acid and vitamin E.

[0024] In another embodiment, the invention provides for use of any recombinant AAV vector of the invention for the preparation of a medicament for treatment of muscular dystrophy or chronic muscle wasting syndrome in a subject in need thereof. In addition, the invention provides for use of any of the recombinant AAV vectors of the invention for the preparation of a medicament for regenerating muscle in subject need thereof. In one aspect, the medicament is administered to a subject having recessive mutation in the ANO5 gene. In another aspect, the medicament of the invention is administered to a subject in suffering from muscular dystrophy such as dysferlin-associated muscular dystrophy, limb girdle muscular dystrophy type 2L, Miyoshi myopathy type 3, Bethlem myopathy, calpainopathy, desmin myopathy, dysferlinopathy, myofibrillar myopathy, sarcoglycanopathie or ZASP-related myopathy. Any of the medicaments of the invention are formulated for intramuscular or intravenous injection. Any of the medicaments of the invention further comprise a

therapeutically effective amount of an antioxidant composition. For example, the antioxidant composition comprises at least one of a coenzyme Q10, lipoic acid, vitamin, carotenoid, vitamin cofactor, mineral, polyphenol, or flavonoid. In particular, the antioxidant composition comprises coenzyme Q10, lipoic acid and vitamin E.

- 5 **[0025]** In another embodiment, the invention provides for methods of treating muscular dystrophy or chronic muscle wasting comprising administering a therapeutically effective amount of antioxidant composition to a subject in need thereof. The antioxidant composition comprises at least one of a coenzyme Q10, lipoic acid, vitamin, carotenoid, vitamin cofactor, mineral, polyphenol, or flavonoid.
- 10 In some aspects, the antioxidant composition comprises coenzyme Q10, lipoic acid and vitamin E. In one aspect, the subject in need has a recessive mutation in the ANO5 gene. In another aspect, oxidative stress is reduced in skeletal muscle of the subject. In another aspect, the skeletal muscle function of the subject is improved. The In another aspect, the subject is suffering from dysferlin-associated muscular
- 15 dystrophy, limb girdle muscular dystrophy type 2L, Miyoshi myopathy type 3, Bethlem myopathy, calpainopathy, desmin myopathy, dysferlinopathy, myofibrillar myopathy, sarcoglycanopathie or ZASP-related myopathy.

- [0026]** The invention also provides for methods for slowing the progression of muscular dystrophy or chronic muscle wasting comprising administering a
- 20 therapeutically effective amount of an antioxidant composition to a subject in need thereof. The antioxidant composition comprises at least one of a coenzyme Q10, lipoic acid, vitamin, carotenoid, vitamin cofactor, mineral, polyphenol, or flavonoid. In some aspects, the antioxidant composition comprises coenzyme Q10, lipoic acid and vitamin E. In one aspect, the subject in need has a recessive mutation in the
- 25 ANO5 gene. In another aspect, oxidative stress is reduced in skeletal muscle of the subject. In another aspect, the skeletal muscle function of the subject is improved. In another aspect, the subject is suffering from dysferlin-associated muscular dystrophy, limb girdle muscular dystrophy type 2L, Miyoshi myopathy type 3, Bethlem myopathy, calpainopathy, desmin myopathy, dysferlinopathy, myofibrillar myopathy,
- 30 sarcoglycanopathie or ZASP-related myopathy.

[0027] In any of the methods of the invention, the antioxidant composition is administered orally. In any of the methods of the invention, the antioxidants are

administered in the same composition or the antioxidants are administered in separate compositions. If the antioxidants are administered separately but concurrently. In addition, in any of the methods of the invention, the antioxidants are administered at separate times or consecutively. In any of the methods of the invention, the

5 antioxidant composition is administered once daily, once weekly, twice weekly, once every two weeks, once every three weeks, monthly or once every two months.

[0028] The invention also provides for a composition comprising a therapeutically effective amount of an antioxidant composition. The antioxidant composition comprises at least one of a coenzyme Q10, lipoic acid, vitamin, carotenoid, vitamin
10 cofactor, mineral, polyphenol, or flavonoid for the treatment of muscular dystrophy or chronic muscle wasting syndrome in a subject in need.

[0029] The invention also provides for composition comprising a therapeutically effective amount of an antioxidant composition. The antioxidant compositions comprises at least one of a coenzyme Q10, lipoic acid, vitamin, carotenoid, vitamin
15 cofactor, mineral, polyphenol, or flavonoid for slowing the progression of muscular dystrophy or chronic muscle wasting in a subject in need. In some aspects, the antioxidant composition comprises coenzyme Q10, lipoic acid and vitamin E.

[0030] In one aspect, any of the compositions of the invention is administered to a subject having recessive mutation in the ANO5 gene. In another aspect, oxidative
20 stress is reduced in skeletal muscle of the subject after administration of the composition. In another aspect, the skeletal muscle function of the subject is improved after administration of the composition. In another aspect, any of the compositions of the invention is administered to a subject suffering from muscular dystrophy such as dysferlin-associated muscular dystrophy, limb girdle muscular dystrophy type 2L,
25 Miyoshi myopathy type 3, Bethlem myopathy, calpainopathy, desmin myopathy, dysferlinopathy, myofibrillar myopathy, sarcoglycanopathie or ZASP-related myopathy. Any of the compositions of the invention are formulated for intramuscular or intravenous injection.

[0031] In another embodiment, the invention provides for use of an antioxidant
30 composition for the preparation of a medicament for the treatment of muscular dystrophy or chronic muscle wasting syndrome in a subject in need thereof. The antioxidant composition in any of the medicaments of the invention comprises at least

one of a coenzyme Q10, lipoic acid, vitamin, carotenoid, vitamin cofactor, mineral, polyphenol, or flavonoid.

[0032] In addition, the invention provides for use of an antioxidant composition for the preparation of a medicament for regenerating muscle in a subject in need thereof.

5 The antioxidant composition in any of the medicaments of the invention comprises at least one of a coenzyme Q10, lipoic acid, vitamin, carotenoid, vitamin cofactor, mineral, polyphenol, or flavonoid. In some aspects, the antioxidant composition comprises coenzyme Q10, lipoic acid and vitamin E.

[0033] In addition, the invention provides for use of an antioxidant composition for
10 the preparation of a medicament for slowing the progression of muscular dystrophy or muscle wasting syndrome in a subject in need thereof. The antioxidant composition in any of the medicaments of the invention comprises at least one of a coenzyme Q10, lipoic acid, vitamin, carotenoid, vitamin cofactor, mineral, polyphenol, or flavonoid. In some aspects, the antioxidant composition comprises coenzyme Q10, lipoic acid
15 and vitamin E.

[0034] Any of the medicaments of the invention are administered to a subject having recessive mutation in the ANO5 gene. In another aspect, oxidative stress is reduced in skeletal muscle of the subject. In another aspect, the skeletal muscle function of the subject is improved. In another aspect, any of the medicaments of the
20 invention is administered to a subject in suffering from muscular dystrophy such as dysferlin-associated muscular dystrophy, limb girdle muscular dystrophy type 2L, Miyoshi myopathy type 3, Bethlem myopathy, calpainopathy, desmin myopathy, dysferlinopathy, myofibrillar myopathy, sarcoglycanopathy or ZASP-related myopathy. In addition, any of the medicaments of the invention are formulated for
25 intramuscular or intravenous injection.

[0035] In some embodiments, the antioxidant composition is administered orally. In some aspects, the antioxidants are in the same composition. In other aspects, the antioxidants are in separate compositions. In some aspects, the antioxidants of the antioxidant composition are administered concurrently. In some aspects, the
30 antioxidants of the antioxidant composition are administered at separate times or consecutively. In some embodiments, the antioxidant composition is administered

once daily, once weekly, twice weekly, once every two weeks, once every three weeks, monthly or once every two months.

BRIEF DESCRIPTION OF DRAWINGS

[0036] **Figure 1A-1D** illustrates generation of the *Ano5*^{-/-} mouse model. **Panel (a)** shows an *Ano5* targeting vector comprising an exogenous intron and *lacZ* -encoding exon with a polyadenylation termination signal. The resulting mRNA terminates with exon 8. **Panel (b)** show genomic DNA isolated from tail clippings of littermates. Lane 1– wild type (WT) mouse, Lanes 2 *Ano5*^{+/-} mouse, Lane 3 *Ano5*^{-/-} mouse, WT allele–300 bp fragment, *Ano5* allele – 200 bp fragment. **Panel (c)** displays products from RT-PCR displaying no evidence of the *Ano5* transcript in *Ano5*^{-/-} muscle tissue using two primer sets targeting *Ano5*. Lane 1: *GAPDH* control; lane 2 e10-14 primers spanning exons 10-14; lane 3 e17-20 primers spanning exons 17-20. **Panel (d)** demonstrates >99% relative expression reduction of ANO5 at the RNA level was confirmed through qRT-PCR in quadriceps (QD), gastrocnemius (GAS) and tibialis anterior (TA) muscle extracted from the *Ano5*^{-/-} mouse (P <0.001).

[0037] **Figure 2A- 2F** illustrates the characterization of *Ano5*^{-/-} deficient mice. Panel (a) demonstrates that serum creatine kinase is significantly elevated in *Ano5*^{-/-} mice at 9 months (P<0.05, t-test). Panel (b) demonstrates specific force of contraction of diaphragm strips from 9 months old *Ano5*^{-/-} mice was significantly decreased compared to controls (P<0.01, t-test). Panel (c) demonstrates that the specific force of contraction of EDL and tibialis anterior (TA) muscles from 9 month *Ano5*^{-/-} mice were not significantly different than controls (P>0.05, t-test). Panel (d) depicts hematoxylin and eosin stained tissue sections demonstrating mild dystrophic pathology including central nuclei, fiber size variability, and areas of necrosis in the TA and GAS of the *Ano5*^{-/-} mouse compared to WT controls. Scale Bar = 50µm. Panel (e) provides muscle fiber diameter measurements showing a reduction in fiber diameter size compared to WT, especially in GAS muscle (P<0.0001, t-test). Panel (f) exhibits that *Ano5*^{-/-} mice demonstrated frequent pauses when treadmill exhaustion studies were performed.

[0038] **Figure 3A-3E** provides physiological characterization of *Ano5*^{-/-} mice. **Panel (a)** Lactic acid levels were slightly reduced in *Ano5*^{-/-} mice compared to WT controls following treadmill running (P=0.15). **Panel (b)** Electrophysiological

- characteristics of the muscle. CMAP amplitude was not significantly difference between *Ano5*^{-/-} (45.1±2.2 mV) and WT (40.8±2.4 mV) (p=0.22). No *Ano5*^{-/-} or WT animal demonstrated fibrillation potentials. **Panels (c-e)** Impedance characteristics of muscle at 50 kHz (phase; reactance; resistance, respectively). There were no
- 5 differences between *Ano5*^{-/-} (31.0±2.7; 248.1±37.8 Ω; 411.4±34.6 Ω) and WT fibers (31.7±3.9; 269.0±83.9 Ω; 424.3±73.9 Ω) (phase: p=0.59; reactance: p=0.44; resistance: p=0.59). No differences were observed at 100 kHz between *Ano5*^{-/-} (36.5±2.4; 216.2±27.3 Ω; 290.7±22.0 Ω) and WT fibers (37.0±4.8; 228.4±63.9 Ω; 295.8±36.1 Ω) (phase: p=0.77; reactance: p=0.55; resistance: p=0.68).
- 10 **[0039] Figure 4A – 4G** provides subcellular histopathology in *Ano5*^{-/-} muscle. **Panel (a)** provides Gomori Trichrome stain of 10 mo *Ano5*^{-/-} and WT TA muscles. *Ano5*^{-/-} muscle contains membrane aggregates (arrows). Scale Bar = 20μm **Panel (b)** provides quantification of the number of fibers containing aggregates in TA and GAS muscles of the *Ano5*^{-/-} compared to WT (p<0.0001, one-way ANOVA). **Panels (c,d)**
- 15 provide electron microscopic images demonstrating the presence of membrane aggregates in *Ano5*^{-/-} muscle. Aggregates were either loosely packed, interconnecting tubular formations with fuzzy inner tubules (white arrows) or densely packed accumulations of vesicular or tubular membranes (black arrows). Scale bars = 500nm. **Panel (e)** demonstrates sub-sarcolemmal accumulations of mitochondria (arrows) and
- 20 degenerating mitochondria (asterisk) were frequently identified by electron microscopy in *Ano5*^{-/-} muscle. Scale bars = 500nm (left) and 2μm (right). **Panel (f)** provides succinate dehydrogenase staining of 10 mo *Ano5*^{-/-} TA muscle showed sarcolemmal thickening and capped fibers that were not present in WT. Scale bars = 10μm. **Panel (g)** provides cryosections of the TA muscle from 10 mo *Ano5*^{-/-} mice
- 25 were stained for succinate dehydrogenase (SDH). Arrows indicate aggregates that do not stain for SDH (left). Serial sections from 10 mo *Ano5*^{-/-} mice demonstrate that many membrane aggregates (white arrows) observed with trichrome staining are positive for SERCA1 (right) suggesting they are derived from the sarcoplasmic reticulum. Scale Bar = 40μm.
- 30 **[0040] Figure 5A- 4E** demonstrates that membrane repair is defective in *Ano5*^{-/-} mice. **Panel (a)** provides images of *Ano5*^{-/-} and WT muscle fibers damaged by a laser pulse shown 5 sec and 190 sec post-injury. Red arrows indicate the site of damage

with FM1-43 dye accumulating quickly in *Ano5*^{-/-} muscle compared to WT. Scale Bar = 50µm. **Panel (b)** provides measurement of fluorescence intensity after laser-induced injury. *Ano5*^{-/-} muscle is statistically different from WT and AAV.ANO5 fibers at all times >100 seconds post-injury (2-way ANOVA, P<0.001). **Panel (c)** exhibits expression of ANO5-FLAG in *Ano5*^{-/-} muscles injected with 5 x10¹⁰ vg AAV.ANO5.FLAG vector. Immunofluorescence with anti-FLAG antibody demonstrated ANO5-FLAG expression at the cell surface in treated muscle (top) that was absent in untreated *Ano5*^{-/-} muscle (bottom). Scale bar = 40µm **Panel (d)** demonstrates recovery from cardiotoxin-induced muscle damage. Hematoxylin and eosin stained tissue sections of WT and *Ano5*^{-/-} TA muscles at 1, 3, 7, 14, 30 and 90 days post cardiotoxin injection (d 3,7,14 and 30 shown). *Ano5*^{-/-} muscle incurred more damage and showed an impairment in regeneration compared to WT. **Panel (e)** demonstrates myofiber size remains statistically smaller in *Ano5*^{-/-} muscle compared to WT at 30 d (Cardiotoxin D30) and 90 d (Cardiotoxin D90) post cardiotoxin injection (P<0.05, t-test).

[0041] **Figure 6** demonstrates the voluntary activity for *Ano5*^{-/-} mice treated with antioxidant therapy or placebo diet. The graph shows the voluntary activity (number of times mice broke horizontal and/or vertical laser beams in a 45 minute period) for *Ano5*^{-/-} mice receiving antioxidant diet or placebo control for 12 and 16 weeks. *Ano5*^{-/-} mice treated with triple antioxidant therapy has significantly increased activity compared to placebo treated at 16 weeks.

[0042] **Figure 7** shows specific force measurements on the diaphragm of *Ano5*^{-/-} given either a triple antioxidant therapy or placebo diet and WT control mice on placebo diet. *Ano5*^{-/-} mice treated with triple antioxidant therapy exhibited significantly increased diaphragm specific force compared to placebo treated at 16 weeks.

[0043] **Figure 8A-8B** demonstrates the effect triple antioxidant therapy mitochondrial biogenesis and function. Male gastrocnemius muscle tissue was used to measure mitochondrial biogenesis marker, mitochondrial biogenesis *PGC-1α* expression and citrate synthase activity in triple antioxidant-fed mice. **Panel (a)** shows *PGC-1α* expression for mice given either an triple antioxidant therapy or

placebo diet. **Panel (b)** shows citrate synthase (CS) activity for male and female *Ano5*^{-/-} and WT mice given either a triple antioxidant therapy or placebo diet.

DETAILED DESCRIPTION

[0044] ANO5 plays an essential role in muscle repair and the invention provides
5 for AAV vectors comprising the ANO5 gene for treatment of MD. Disruption of
ANO5 closely phenocopies the loss of dysferlin expression in murine models, and
dysferlin mutations cause MDs similar to ANO5 myopathies (limb girdle muscular
dystrophy 2B (LGMD2B) and Miyoshi myopathy dystrophy 1 (MMD1) vs limb
girdle muscular dystrophy 2L (LGMD2L) and Miyoshi myopathy dystrophy 3
10 (MMD3)).

[0045] The *Ano5*^{-/-} mouse represents an important model for the study of ANO5-
myopathy, sarcolemmal repair, and myogenic cell fusion. The experimental evidence
provided in the Examples below support methods for gene replacement therapy as a
treatment strategy for ANO5-myopathy by partially rescuing the membrane repair
15 phenotype via AAV.ANO5-FLAG treatment of *Ano5*^{-/-} mice.

AAV

[0046] As used herein, the term "AAV" is a standard abbreviation for adeno-
associated virus. Adeno-associated virus is a single-stranded DNA parvovirus that
grows only in cells in which certain functions are provided by a co-infecting helper
20 virus. There are currently thirteen serotypes of AAV that have been characterized, as
shown below in Table 1. General information and reviews of AAV can be found in,
for example, Carter, 1989, Handbook of Parvoviruses, Vol. 1, pp. 169-228, and Berns,
1990, Virology, pp. 1743-1764, Raven Press, (New York). However, it is fully
expected that these same principles will be applicable to additional AAV serotypes
25 since it is well known that the various serotypes are quite closely related, both
structurally and functionally, even at the genetic level. (See, for example, Blacklowe,
1988, pp. 165-174 of Parvoviruses and Human Disease, J. R. Pattison, ed.; and Rose,
Comprehensive Virology 3:1-61 (1974)). For example, all AAV serotypes apparently
exhibit very similar replication properties mediated by homologous rep genes; and all
30 bear three related capsid proteins such as those expressed in AAV2. The degree of
relatedness is further suggested by heteroduplex analysis which reveals extensive

cross-hybridization between serotypes along the length of the genome; and the presence of analogous self-annealing segments at the termini that correspond to "inverted terminal repeat sequences" (ITRs). The similar infectivity patterns also suggest that the replication functions in each serotype are under similar regulatory control.

5 [0047] An "AAV vector" as used herein refers to a vector comprising one or more polynucleotides of interest (or transgenes) that are flanked by AAV terminal repeat sequences (ITRs). Such AAV vectors can be replicated and packaged into infectious viral particles when present in a host cell that has been transfected with a vector encoding and expressing rep and cap gene products.

10 [0048] An "AAV virion" or "AAV viral particle" or "AAV vector particle" refers to a viral particle composed of at least one AAV capsid protein and an encapsidated polynucleotide AAV vector. If the particle comprises a heterologous polynucleotide (i.e. a polynucleotide other than a wild-type AAV genome such as a transgene to be delivered to a mammalian cell), it is typically referred to as an "AAV vector particle" or simply an "AAV vector". Thus, production of AAV vector particle necessarily includes production of AAV vector, as such a vector is contained within an AAV vector particle.

15 [0049] An AAV vector may be either single-stranded or double-stranded nucleic acid, having an AAV 5' inverted terminal repeat (ITR) sequence and an AAV 3' ITR flanking a protein-coding sequence operably linked to transcription regulatory elements, i.e., one or more promoters and/or enhancers, and a polyadenylation sequence, and, optionally, one or more introns inserted between exons of the protein-coding sequence. A single-stranded AAV vector refers to nucleic acids that are present in the genome of an AAV virus particle, and can be either the sense strand or the anti-sense strand of the nucleic acid sequences disclosed herein. The size of such single-stranded nucleic acids is provided in bases. A double-stranded AAV vector refers to nucleic acids that are present in the DNA of plasmids, e.g., pUC19, or genome of a double-stranded virus, e.g., baculovirus, used to express or transfer the AAV vector nucleic acids. The size of such double-stranded nucleic acids is provided in base pairs (bp).

[0050] The term “inverted terminal repeat (ITR)” as used herein refers to the art-recognized regions found at the 5’ and 3’ termini of the AAV genome which function in cis as origins of DNA replication and as packaging signals for the viral genome. AAV ITRs, together with the AAV rep coding region, provide for efficient excision and rescue from, and integration of a nucleotide sequence interposed between two flanking ITRs into a host cell genome. Sequences of certain AAV-associated ITRs are disclosed by Yan *et al.*, J. Virol. 79(1):364-379 (2005) which is herein incorporated by reference in its entirety.

[0051] A “transcription control element” refers to nucleotide sequences of a gene involved in regulation of genetic transcription including a promoter, plus response elements, activator and enhancer sequences for binding of transcription factors to aid RNA polymerase binding and promote expression, and operator or silencer sequences to which repressor proteins bind to block RNA polymerase attachment and prevent expression.

[0052] AAV “rep” and “cap” genes are genes encoding replication and encapsidation proteins, respectively. AAV rep and cap genes have been found in all AAV serotypes examined to date, and are described herein and in the references cited. In wild-type AAV, the rep and cap genes are generally found adjacent to each other in the viral genome (i.e., they are “coupled” together as adjoining or overlapping transcriptional units), and they are generally conserved among AAV serotypes. AAV rep and cap genes are also individually and collectively referred to as “AAV packaging genes.” The AAV cap gene in accordance with the present invention encodes a Cap protein which is capable of packaging AAV vectors in the presence of rep and adeno helper function and is capable of binding target cellular receptors. In some embodiments, the AAV cap gene encodes a capsid protein having an amino acid sequence derived from a particular AAV serotype, for example the serotypes shown in Table 1 and AAV rh.74 (see U.S. Patent 9,434,928). Other types of rAAV variants, for example rAAV with capsid mutations, are also contemplated. See, for example, Marsic *et al.*, Mol Ther, 22(11): 1900-1909 (2014).

[0053] **Table 1. AAV serotypes**

AAV Serotype	Genbank Accession No.
AAV-1	NC_002077.1

AAV-2	NC_001401.2
AAV-3	NC_001729.1
AAV-3B	AF028705.1
AAV-4	NC_001829.1
AAV-5	NC_006152.1
AAV-6	AF028704.1
AAV-7	NC_006260.1
AAV-8	NC_006261.1
AAV-9	AX753250.1
AAV-10	AY631965.1
AAV-11	AY631966.1
AAV-12	DQ813647.1
AAV-13	EU285562.1

[0054] The AAV sequences employed for the production of AAV can be derived from the genome of any AAV serotype. Generally, the AAV serotypes have genomic sequences of significant homology at the amino acid and the nucleic acid levels, provide a similar set of genetic functions, produce virions which are essentially physically and functionally equivalent, and replicate and assemble by practically identical mechanisms. For the genomic sequence of AAV serotypes and a discussion of the genomic similarities see, for example, GenBank Accession number U89790; GenBank Accession number J01901; GenBank Accession number AF043303; GenBank Accession number AF085716; Chlorini *et al.*, J. Vir. 71: 6823-33(1997); Srivastava *et al.*, J. Vir. 45:555-64 (1983); Chlorini *et al.*, J. Vir. 73:1309-1319 (1999); Rutledge *et al.*, J. Vir. 72:309-319 (1998); and Wu *et al.*, J. Vir. 74: 8635-47 (2000).

[0055] The genomic organization of all known AAV serotypes is very similar. The genome of AAV is a linear, single-stranded DNA molecule that is less than about 5,000 nucleotides (nt) in length. Inverted terminal repeats (ITRs) flank the unique coding nucleotide sequences for the non-structural replication (Rep) proteins and the structural (VP) proteins. The VP proteins form the capsid. The terminal 145 nt are self-complementary and are organized so that an energetically stable intramolecular duplex forming a T-shaped hairpin may be formed. These hairpin structures function as an origin for viral DNA replication, serving as primers for the cellular DNA polymerase complex. The Rep genes encode the Rep proteins, Rep78, Rep68, Rep52, and Rep40. Rep78 and Rep68 are transcribed from the p5 promoter, and Rep 52 and

Rep40 are transcribed from the p19 promoter. The cap genes encode the VP proteins, VP1, VP2, and VP3. The cap genes are transcribed from the p40 promoter.

[0056] In some embodiments, a nucleic acid sequence encoding an AAV capsid protein is operably linked to expression control sequences for expression in a specific cell type, such as Sf9 or HEK cells. Techniques known to one skilled in the art for expressing foreign genes in insect host cells or mammalian host cells can be used to practice the invention. Methodology for molecular engineering and expression of polypeptides in insect cells is described, for example, in Summers and Smith. 1986. A Manual of Methods for Baculovirus Vectors and Insect Culture Procedures, Texas Agricultural Experimental Station Bull. No. 7555, College Station, Tex.; Luckow. 1991. In Prokop *et al.*, Cloning and Expression of Heterologous Genes in Insect Cells with Baculovirus Vectors' Recombinant DNA Technology and Applications, 97-152; King, L. A. and R. D. Possee, 1992, The baculovirus expression system, Chapman and Hall, United Kingdom; O'Reilly, D. R., L. K. Miller, V. A. Luckow, 1992, Baculovirus Expression Vectors: A Laboratory Manual, New York; W.H. Freeman and Richardson, C. D., 1995, Baculovirus Expression Protocols, Methods in Molecular Biology, volume 39; U.S. Pat. No. 4,745,051; US2003148506; and WO 03/074714. A particularly suitable promoter for transcription of a nucleotide sequence encoding an AAV capsid protein is e.g. the polyhedron promoter. However, other promoters that are active in insect cells are known in the art, e.g. the p10, p35 or IE-1 promoters and further promoters described in the above references are also contemplated.

[0057] Use of insect cells for expression of heterologous proteins is well documented, as are methods of introducing nucleic acids, such as vectors, e.g., insect-cell compatible vectors, into such cells and methods of maintaining such cells in culture. See, for example, METHODS IN MOLECULAR BIOLOGY, ed. Richard, Humana Press, NJ (1995); O'Reilly *et al.*, BACULOVIRUS EXPRESSION VECTORS, A LABORATORY MANUAL, Oxford Univ. Press (1994); Samulski *et al.*, J. Vir. 63:3822-8 (1989); Kajigaya *et al.*, Proc. Nat'l. Acad. Sci. USA 88: 4646-50 (1991); Ruffing *et al.*, J. Vir. 66:6922-30 (1992); Kirnbauer *et al.*, Vir. 219:37-44 (1996); Zhao *et al.*, Vir. 272:382-93 (2000); and Samulski *et al.*, U.S. Pat. No. 6,204,059. In some embodiments, the nucleic acid construct encoding AAV in insect

cells is an insect cell-compatible vector. An "insect cell-compatible vector" or "vector" as used herein refers to a nucleic acid molecule capable of productive transformation or transfection of an insect or insect cell. Exemplary biological vectors include plasmids, linear nucleic acid molecules, and recombinant viruses.

- 5 Any vector can be employed as long as it is insect cell-compatible. The vector may integrate into the insect cells genome but the presence of the vector in the insect cell need not be permanent and transient episomal vectors are also included. The vectors can be introduced by any means known, for example by chemical treatment of the cells, electroporation, or infection. In some embodiments, the vector is a baculovirus, a viral vector, or a plasmid. In a more preferred embodiment, the vector is a
10 baculovirus, i.e. the construct is a baculoviral vector. Baculoviral vectors and methods for their use are described in the above cited references on molecular engineering of insect cells.

- [0058] Baculoviruses are enveloped DNA viruses of arthropods, two members of
15 which are well known expression vectors for producing recombinant proteins in cell cultures. Baculoviruses have circular double-stranded genomes (80-200 kbp) which can be engineered to allow the delivery of large genomic content to specific cells. The viruses used as a vector are generally *Autographa californica* multicapsid nucleopolyhedrovirus (AcMNPV) or *Bombyx mori* (Bm)NPV (Kato et al., 2010).

- 20 [0059] Baculoviruses are commonly used for the infection of insect cells for the expression of recombinant proteins. In particular, expression of heterologous genes in insects can be accomplished as described in for instance U.S. Pat. No. 4,745,051; Friesen et al (1986); EP 127,839; EP 155,476; Vlak et al (1988); Miller et al (1988); Carbonell et al (1988); Maeda et al (1985); Lebacqz-Verheyden et al (1988); Smith et
25 al (1985); Miyajima et al (1987); and Martin et al (1988). Numerous baculovirus strains and variants and corresponding permissive insect host cells that can be used for protein production are described in Luckow et al (1988), Miller et al (1986); Maeda et al (1985) and McKenna (1989).

- [0060] In one aspect, the invention provides rAAV genomes. The rAAV genomes
30 comprise one or more AAV ITRs flanking a polynucleotide sequence encoding the ANO5 protein. If the polynucleotide encodes ANO5 protein, the polynucleotide is operatively linked to transcriptional control DNA, specifically promoter DNA and

polyadenylation signal sequence DNA that are functional in target cells, e.g. muscle cells, to form a gene cassette. The gene cassette may also include intron sequences to facilitate processing of the RNA transcript when expressed in mammalian cells. For example, the AAV genome comprises one or more AAV ITRs flanking one or more
5 exons of the ANO5 gene, such as exon 8 and exon 9 of the ANO5 gene. The AAV genome may also comprise one or more of the following: an intron, a report gene such as Lac-Z β -galactosidase or neomycin resistance gene, CRE-Lox recombination sites such as Lox P, and an internal ribosome entry site (IRES).

Methods for Producing Recombinant AAVs

10 [0061] The present disclosure provides materials and methods for producing recombinant AAVs in insect or mammalian cells. In some embodiments, the viral construct further comprises a promoter and a restriction site downstream of the promoter to allow insertion of a polynucleotide encoding one or more proteins of interest, wherein the promoter and the restriction site are located downstream of the 5'
15 AAV ITR and upstream of the 3' AAV ITR. In some embodiments, the viral construct further comprises a posttranscriptional regulatory element downstream of the restriction site and upstream of the 3' AAV ITR. In some embodiments, the viral construct further comprises a polynucleotide inserted at the restriction site and operably linked with the promoter, where the polynucleotide comprises the coding
20 region of a protein of interest. As a skilled artisan will appreciate, any one of the AAV vector disclosed in the present application can be used in the method as the viral construct to produce the recombinant AAV. The DNA plasmids are transferred to cells permissible for infection with a helper virus of AAV (e.g., adenovirus, E1-deleted adenovirus or herpesvirus) for assembly of the rAAV genome into infectious
25 viral particles. Techniques to produce rAAV particles, in which an AAV genome to be packaged, rep and cap genes, and helper virus functions are provided to a cell are standard in the art. Production of rAAV requires that the following components are present within a single cell (denoted herein as a packaging cell): a rAAV genome, AAV rep and cap genes separate from (*i.e.*, not in) the rAAV genome, and helper
30 virus functions.

[0062] In some embodiments, the helper functions are provided by one or more helper plasmids or helper viruses comprising adenoviral or baculoviral helper genes.

Non-limiting examples of the adenoviral or baculoviral helper genes include, but are not limited to, E1A, E1B, E2A, E4 and VA, which can provide helper functions to AAV packaging.

[0063] Helper viruses of AAV are known in the art and include, for example, viruses from the family *Adenoviridae* and the family *Herpesviridae*. Examples of helper viruses of AAV include, but are not limited to, SAdV-13 helper virus and SAdV-13-like helper virus described in US Publication No. 20110201088 (the disclosure of which is incorporated herein by reference), helper vectors pHELP (Applied Viromics). A skilled artisan will appreciate that any helper virus or helper plasmid of AAV that can provide adequate helper function to AAV can be used herein.

[0064] In some embodiments, the AAV cap genes are present in a plasmid. The plasmid can further comprise an AAV rep gene. The cap genes and/or rep gene from any AAV serotype (including, but not limited to, AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13, AAV rh.74 and any variants thereof) can be used herein to produce the recombinant AAV. In some embodiments, the AAV cap genes encode a capsid from serotype 1, serotype 2, serotype 4, serotype 5, serotype 6, serotype 7, serotype 8, serotype 9, serotype 10, serotype 11, serotype 12, serotype 13 or a variant thereof.

[0065] In some embodiments, the insect or mammalian cell can be transfected with the helper plasmid or helper virus, the viral construct and the plasmid encoding the AAV cap genes; and the recombinant AAV virus can be collected at various time points after co-transfection. For example, the recombinant AAV virus can be collected at about 12 hours, about 24 hours, about 36 hours, about 48 hours, about 72 hours, about 96 hours, about 120 hours, or a time between any of these two time points after the co-transfection.

[0066] Recombinant AAV can also be produced using any conventional methods known in the art suitable for producing infectious recombinant AAV. In some instances, a recombinant AAV can be produced by using an insect or mammalian cell that stably expresses some of the necessary components for AAV particle production. For example, a plasmid (or multiple plasmids) comprising AAV rep and cap genes, and a selectable marker, such as a neomycin resistance gene, can be integrated into

the genome of the cell. The insect or mammalian cell can then be co-infected with a helper virus (e.g., adenovirus or baculovirus providing the helper functions) and the viral vector comprising the 5' and 3' AAV ITR (and the nucleotide sequence encoding the heterologous protein, if desired). The advantages of this method are that the cells
5 are selectable and are suitable for large-scale production of the recombinant AAV. As another non-limiting example, adenovirus or baculovirus rather than plasmids can be used to introduce rep and cap genes into packaging cells. As yet another non-limiting example, both the viral vector containing the 5' and 3' AAV LTRs and the rep-cap genes can be stably integrated into the DNA of producer cells, and the helper
10 functions can be provided by a wild-type adenovirus to produce the recombinant AAV.

[0067] A method of generating a packaging cell is to create a cell line that stably expresses all the necessary components for AAV particle production. For example, a plasmid (or multiple plasmids) comprising a rAAV genome lacking AAV rep and cap
15 genes, AAV rep and cap genes separate from the rAAV genome, and a selectable marker, such as a neomycin resistance gene, are integrated into the genome of a cell. AAV genomes have been introduced into bacterial plasmids by procedures such as GC tailing (Samulski et al., 1982, Proc. Natl. Acad. Sci. USA, 79:2077-2081), addition of synthetic linkers containing restriction endonuclease cleavage sites
20 (Laughlin et al., 1983, Gene, 23:65-73) or by direct, blunt-end ligation (Senapathy & Carter, 1984, J. Biol. Chem., 259:4661-4666). The packaging cell line is then infected with a helper virus such as adenovirus. The advantages of this method are that the cells are selectable and are suitable for large-scale production of rAAV. Other examples of suitable methods employ adenovirus or baculovirus rather than
25 plasmids to introduce rAAV genomes and/or rep and cap genes into packaging cells.

[0068] General principles of rAAV production are reviewed in, for example, Carter, 1992, Current Opinions in Biotechnology, 1533-539; and Muzyczka, 1992, Curr. Topics in Microbial. and Immunol., 158:97-129). Various approaches are described in Ratschin et al., Mol. Cell. Biol. 4:2072 (1984); Hermonat et al., Proc.
30 Natl. Acad. Sci. USA, 81:6466 (1984); Tratschin et al., Mol. Cell. Biol. 5:3251 (1985); McLaughlin et al., J. Virol., 62:1963 (1988); and Lebkowski et al., 1988 Mol. Cell. Biol., 7:349 (1988). Samulski et al. (1989, J. Virol., 63:3822-3828); U.S. Patent

No. 5,173,414; WO 95/13365 and corresponding U.S. Patent No. 5,658,776 ; WO 95/13392; WO 96/17947; PCT/US98/18600; WO 97/09441 (PCT/US96/14423); WO 97/08298 (PCT/US96/13872); WO 97/21825 (PCT/US96/20777); WO 97/06243 (PCT/FR96/01064); WO 99/11764; Perrin et al. (1995) Vaccine 13:1244-1250; Paul et al. (1993) Human Gene Therapy 4:609-615; Clark et al. (1996) Gene Therapy 3:1124-1132; U.S. Patent. No. 5,786,211; U.S. Patent No. 5,871,982; and U.S. Patent. No. 6,258,595. The foregoing documents are hereby incorporated by reference in their entirety herein, with particular emphasis on those sections of the documents relating to rAAV production.

10 **[0069]** The invention thus provides packaging cells that produce infectious rAAV. In one embodiment packaging cells may be stably transformed cancer cells such as HeLa cells, 293 cells and PerC.6 cells (a cognate 293 line). In another embodiment, packaging cells are cells that are not transformed cancer cells such as low passage 293 cells (human fetal kidney cells transformed with E1 of adenovirus), MRC-5 cells
15 (human fetal fibroblasts), WI-38 cells (human fetal fibroblasts), Vero cells (monkey kidney cells) and FRhL-2 cells (rhesus fetal lung cells).

[0070] The rAAV may be purified by methods standard in the art such as by column chromatography or cesium chloride gradients. Methods for purifying rAAV vectors from helper virus are known in the art and include methods disclosed in, for
20 example, Clark *et al.*, *Hum. Gene Ther.*, 10(6): 1031-1039 (1999); Schenpp and Clark, *Methods Mol. Med.*, 69 427-443 (2002); U.S. Patent No. 6,566,118 and WO 98/09657.

Cell Types Used in AAV Production

[0071] The viral particles comprising the AAV vectors of the invention may be
25 introduced using any invertebrate cell type which allows for production of AAV or biologic products and which can be maintained in culture. For example, the insect cell line used can be from *Spodoptera frugiperda*, such as SF9, SF21, SF900+, drosophila cell lines, mosquito cell lines, e.g., *Aedes albopictus* derived cell lines, domestic silkworm cell lines, e.g. Bombyxmori cell lines, *Trichoplusia ni* cell lines
30 such as High Five cells or Lepidoptera cell lines such as *Ascalapha odorata* cell lines. Preferred insect cells are cells from the insect species which are susceptible to baculovirus infection, including High Five, Sf9, Se301, SeIZD2109, SeUCR1, Sf9,

Sf900+, Sf21, BTI-TN-5B1-4, MG-1, Tn368, HzAm1, BM-N, Ha2302, Hz2E5 and Ao38.

5 [0072] Baculoviruses are enveloped DNA viruses of arthropods, two members of which are well known expression vectors for producing recombinant proteins in cell cultures. Baculoviruses have circular double-stranded genomes (80-200 kbp) which can be engineered to allow the delivery of large genomic content to specific cells. The viruses used as a vector are generally *Autographa californica* multicapsid nucleopolyhedrovirus (AcMNPV) or *Bombyx mori* (Bm-NPV) (Kato et al., 2010).

10 [0073] Baculoviruses are commonly used for the infection of insect cells for the expression of recombinant proteins. In particular, expression of heterologous genes in insects can be accomplished as described in for instance U.S. Pat. No. 4,745,051; Friesen et al (1986); EP 127,839; EP 155,476; Vlak et al (1988); Miller et al (1988); Carbonell et al (1988); Maeda et al (1985); Lebacq-Verheyden et al (1988); Smith et al (1985); Miyajima et al (1987); and Martin et al (1988). Numerous baculovirus
15 strains and variants and corresponding permissive insect host cells that can be used for protein production are described in Luckow et al (1988), Miller et al (1986); Maeda et al (1985) and McKenna (1989).

[0074] In another aspect of the invention, the methods of the invention are also carried out with any mammalian cell type which allows for replication of AAV or
20 production of biologic products, and which can be maintained in culture. Preferred mammalian cells used can be HEK293, HeLa, CHO, NS0, SP2/0, PER.C6, Vero, RD, BHK, HT 1080, A549, Cos-7, ARPE-19 and MRC-5 cells.

Compositions

25 [0075] In another embodiment, the invention contemplates compositions comprising rAAV and /or antioxidants of the present invention. These compositions may be used to regenerate, enhance or repair muscle and/or improve muscle function.

[0076] Compositions of the invention comprise rAAV in a pharmaceutically acceptable carrier. The compositions may also comprise other ingredients such as diluents and adjuvants. Acceptable carriers, diluents and adjuvants are nontoxic to
30 recipients and are preferably inert at the dosages and concentrations employed, and include buffers such as phosphate, citrate, or other organic acids; antioxidants; low

molecular weight polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; 5 chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt-forming counterions such as sodium; and/or nonionic surfactants such as Tween, pluronics or polyethylene glycol (PEG).

[0077] Methods of transducing a target cell with rAAV, *in vivo* or *in vitro*, are contemplated by the invention. The *in vivo* methods comprise the step of 10 administering an effective dose, or effective multiple doses, of a composition comprising a rAAV of the invention to an animal (including a human patient) in need thereof. An effective dose, or effective multiple doses, of a combination of compositions comprising a rAAV of the disclosure to a subject) is a dose that prevents, slows progression of, or ameliorates (eliminates or reduces) muscle 15 pathology associated with the disease being treated. An effect on muscle pathology can be demonstrated by an improvement in one or more measures standard in the art such as: absolute muscle specific force; force decrement during eccentric muscle contractions; serum CK level; serum cardiac troponin level; serum MMP9 level; grip strength; limb torque; limb mobility or flexibility; ambulation; 6 minute walk test; 20 knee flexor or extensor strength; maximal voluntary isometric muscle contraction; North Star Ambulatory Assessment; muscle mass, fat reduction, or edema by limb T2-weighted MRI measures; muscle contractures; limb joint angle; heart function (heart rate, cardiac output, percent fractional shortening, stroke volume); respiration (including respiratory rate, blood oxygenation, need for supplemental oxygen); 25 muscle necrosis; muscle regeneration; muscle wasting; muscle inflammation; muscle calcification; muscle central nucleation; muscle size or myofiber size; lifespan; and dystrophin or laminin alpha 2 surrogate protein expression (utrophin, plectin 1, laminin alpha 5, agrin). See, for example, Forbes *et al.*, *Radiology*, 269(1): 198-207 (2013); Govoni *et al.*, *Cell Mol. Life Sci.*, 70(23): 4585-4602 (2013); and 30 Chandrasekharan and Martin, *Methods Enzymol.*, 479: 291-322 (2010). If a dose is administered prior to development of a disease, the administration is prophylactic. If a dose is administered after the development of a disease, the administration is

therapeutic. The treatment of the subject by methods described herein is therefore contemplated to prevent, slow or prevent progression of, diminish the extent of, result in remission (partial or total) of, and/or prolong survival of the disease being treated.

[0078] Combination therapies are also contemplated by the invention.

5 Combination as used herein includes both simultaneous treatment or sequential treatments. Combinations of methods of the invention with standard medical treatments (*e.g.*, corticosteroids for muscular dystrophies) are specifically contemplated, as are combinations with novel therapies. In this respect, it may be conceivable induce expression of ANO5 to reduce or inhibit muscle injury, to
10 enhance muscle, or induce muscle repair, and then provide the secondary treatment. Such secondary treatments for Muscular Dystrophy may include the use of antioxidants (*e.g.* lipoic acid, coenzyme Q10 and α -tocopherol), IGF-1, interfering RNA approaches, exon-skipping, calpain inhibition, dystrophin upregulation, and dystroglycan expression. Further, there may be additions to expression of ANO5 to
15 enhance the muscle boosting effects. For example, addition of IGF-1 or other trophic factors or muscle precursor injections could be performed.

[0079] The dose of rAAV to be administered in methods disclosed herein will vary depending, for example, on the particular rAAV, the mode of administration, the treatment goal, the individual, and the cell type(s) being targeted, and may be
20 determined by methods standard in the art. Titers of each rAAV administered may range from about 1×10^6 , about 1×10^7 , about 1×10^8 , about 1×10^9 , about 1×10^{10} , about 1×10^{11} , about 1×10^{12} , about 1×10^{13} , about 1×10^{14} , or to about 1×10^{15} or more DNase resistant particles (DRP) per ml. Dosages may also be expressed in units of viral genomes (vg) (*i.e.*, 1×10^7 vg, 1×10^8 vg, 1×10^9 vg, 1×10^{10} vg, 1×10^{11} vg, 1×10^{12} vg,
25 1×10^{13} vg, 1×10^{14} vg, 1×10^{15} respectively). Methods for titering AAV are described in Clark *et al.*, *Hum. Gene Ther.*, 10: 1031-1039 (1999).

[0080] Administration of an effective dose of the compositions may be by routes standard in the art including, but not limited to, intramuscular, parenteral, intravenous, oral, buccal, nasal, pulmonary, intracranial, intraosseous, intraocular, rectal, or
30 vaginal. Route(s) of administration and serotype(s) of AAV components of rAAV (in particular, the AAV ITRs and capsid protein) of the invention may be chosen and/or matched by those skilled in the art taking into account the disease state being treated

and the target cells/tissue(s) that are to express the ANO5 protein. In some embodiments, the route is one or more intramuscular injections into the quadriceps of the patient. In some embodiments, the route is one or more intramuscular injections into each of the three major muscle groups of the quadriceps of the patient.

5 **[0081]** In particular, actual administration of rAAV of the present invention may be accomplished by using any physical method that will transport the rAAV recombinant vector into the target tissue of an animal. Administration according to the invention includes, but is not limited to, injection into muscle, the bloodstream and/or directly into the liver. Simply resuspending a rAAV in phosphate buffered saline has been
10 demonstrated to be sufficient to provide a vehicle useful for muscle tissue expression, and there are no known restrictions on the carriers or other components that can be co-administered with the rAAV (although compositions that degrade DNA should be avoided in the normal manner with rAAV). Capsid proteins of a rAAV may be modified so that the rAAV is targeted to a particular target tissue of interest such as
15 muscle. See, for example, WO 02/053703, the disclosure of which is incorporated by reference herein. Pharmaceutical compositions can be prepared as injectable formulations or as topical formulations to be delivered to the muscles by transdermal transport. Numerous formulations for both intramuscular injection and transdermal transport have been previously developed and can be used in the practice of the
20 invention. The rAAV can be used with any pharmaceutically acceptable carrier for ease of administration and handling.

[0082] For purposes of intramuscular injection, solutions in an adjuvant such as sesame or peanut oil or in aqueous propylene glycol can be employed, as well as sterile aqueous solutions. Such aqueous solutions can be buffered, if desired, and the
25 liquid diluent first rendered isotonic with saline or glucose. Solutions of rAAV as a free acid (DNA contains acidic phosphate groups) or a pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxpropylcellulose. A dispersion of rAAV can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof and in oils. Under ordinary conditions of
30 storage and use, these preparations contain a preservative to prevent the growth of microorganisms. In this connection, the sterile aqueous media employed are all readily obtainable by standard techniques well-known to those skilled in the art.

[0083] The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating actions of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, liquid polyethylene glycol and the like), suitable mixtures thereof, and vegetable oils. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of a dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal and the like. In many cases it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by use of agents delaying absorption, for example, aluminum monostearate and gelatin.

[0084] Sterile injectable solutions are prepared by incorporating rAAV in the required amount in the appropriate solvent with various other ingredients enumerated above, as required, followed by filter sterilization. Generally, dispersions are prepared by incorporating the sterilized active ingredient into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and the freeze drying technique that yield a powder of the active ingredient plus any additional desired ingredient from the previously sterile-filtered solution thereof.

[0085] Transduction with rAAV may also be carried out *in vitro*. In one embodiment, desired target muscle cells are removed from the subject, transduced with rAAV and reintroduced into the subject. Alternatively, syngeneic or xenogeneic muscle cells can be used where those cells will not generate an inappropriate immune response in the subject.

- [0086] Suitable methods for the transduction and reintroduction of transduced cells into a subject are known in the art. In one embodiment, cells can be transduced *in vitro* by combining rAAV with muscle cells, *e.g.*, in appropriate media, and screening for those cells harboring the DNA of interest using conventional techniques such as
- 5 Southern blots and/or PCR, or by using selectable markers. Transduced cells can then be formulated into pharmaceutical compositions, and the composition introduced into the subject by various techniques, such as by intramuscular, intravenous, subcutaneous and intraperitoneal injection, or by injection into smooth and cardiac muscle, using *e.g.*, a catheter.
- 10 [0087] Transduction of cells with rAAV of the invention results in sustained expression of ANO5 protein. The present invention thus provides methods of administering/delivering rAAV which express ANO5 to an animal, preferably a human being. These methods include transducing tissues (including, but not limited to, tissues such as muscle, organs such as liver and brain, and glands such as salivary
- 15 glands) with one or more rAAV of the present invention. Transduction may be carried out with gene cassettes comprising tissue specific control elements. For example, one embodiment of the invention provides methods of transducing muscle cells and muscle tissues directed by muscle specific control elements, including, but not limited to, those derived from the actin and myosin gene families, such as from
- 20 the myoD gene family [See Weintraub *et al.*, *Science*, 251: 761-766 (1991)], the myocyte-specific enhancer binding factor MEF-2 [Cserjesi and Olson, *Mol Cell Biol* 11: 4854-4862 (1991)], control elements derived from the human skeletal actin gene [Muscat *et al.*, *Mol Cell Biol*, 7: 4089-4099 (1987)], the cardiac actin gene, muscle creatine kinase sequence elements [See Johnson *et al.*, *Mol Cell Biol*, 9:3393-3399
- 25 (1989)] and the murine creatine kinase enhancer (mCK) element such as the MCK7 or tMCK which is triple copies of the mouse mCK, control elements derived from the skeletal fast-twitch troponin C gene, the slow-twitch cardiac troponin C gene and the slow-twitch troponin I gene: hypoza-inducible nuclear factors (Semenza *et al.*, *Proc Natl Acad Sci USA*, 88: 5680-5684 (1991)), steroid-inducible elements and promoters
- 30 including the glucocorticoid response element (GRE) [See Mader and White, *Proc. Natl. Acad. Sci. USA* 90: 5603-5607 (1993)], and other control elements.

[0088] Muscle tissue is an attractive target for *in vivo* gene delivery and gene therapy, because it is not a vital organ and is easy to access. The invention contemplates sustained expression of biologically active ANO5 proteins from transduced myofibers.

5 [0089] By “muscle cell” or “muscle tissue” is meant a cell or group of cells derived from muscle of any kind (for example, skeletal muscle and smooth muscle, *e.g.* from the digestive tract, urinary bladder, blood vessels or cardiac tissue). Such muscle cells may be differentiated or undifferentiated, such as myoblasts, myocytes, myotubes, cardiomyocytes and cardiomyoblasts. Since muscle tissue is readily accessible to the
10 circulatory system, a protein produced and secreted by muscle cells and tissue *in vivo* will logically enter the bloodstream for systemic delivery, thereby providing sustained, therapeutic levels of protein secretion from muscle.

[0090] The term “transduction” is used to refer to the administration/delivery of ANO5 DNA to a recipient cell either *in vivo* or *in vitro*, via a replication-deficient
15 rAAV of the invention resulting in expression of a functional ANO5 protein by the recipient cell.

Antioxidant Compositions

[0091] The production of reactive oxygen species during skeletal muscle contraction is well established. During prolonged exercise, elevated amounts of these
20 oxidants cause damage to proteins and lipids, and lead to activation of multiple stress response signaling pathways (Powers *et al.*, *Free Radic Biol Med* 51: 942-50 (2011)). Consequently, several studies have investigated the use of long-term antioxidant supplementation as a means of alleviating oxidative stress in skeletal muscle. One recent study reported that a formulation of three antioxidants (vitamin E, α -lipoic
25 acid, and coenzyme Q10) supplemented into the diet of female mice improved running performance, as well as markers of mitochondrial function (Abadi *et al.*, *PLoS One*. 8:e60722 (2013)). However, others have reported that a similarly modified diet (vitamin E + α -lipoic acid) reduced mitochondrial biogenesis in rats (Strobel *et al.*, *Med Sci Sports Exerc.* 43:1017-24 (2011)). Currently, there is no
30 consensus in the art on the effect of long-term antioxidant supplementation on skeletal muscle health, and very little attention has been given to muscles weakened by

disease. However, the invention provides evidence that an antioxidant diet provide beneficial effects on the skeletal muscle of $Ano5^{-/-}$ mice.

Antioxidants

[0092] The invention provides for the administration of an antioxidant composition to improve muscle physiology and function in subject suffering from muscular dystrophy. The antioxidant composition disclosed herein utilizes at least one antioxidant. In addition, the invention provides for antioxidant compositions that comprise at least two or at least three antioxidants, and in these compositions the antioxidants will have different cellular functions. Preferred antioxidants are those that have been shown to specifically reverse mitochondrial damage as a product of aging. For example, the invention provides for antioxidant compositions comprising at least one of co-enzyme Q10, α -lipoic acid, carotenoids (α -carotene, β -carotene, lycopene, lutein, astaxanthin, canthaxanthin and zeaxanthin), vitamins such as vitamin A (retinol, 3,4-didehydroretinol, and 3-hydroxyretinol), vitamin C (ascorbic acid), and vitamin E (α -tocopherol), vitamin cofactors, polyphenols and flavonoids (resveratrol, gingerol, curcumin), or Minerals (Iron, Magnesium, Selenium, Copper, Zinc, Manganese, Iodide). In preferred embodiments these antioxidants are coenzyme Q10, vitamin E, α -lipoic acid.

[0093] Coenzyme Q10, also known as Q10, vitamin Q10, ubiquinone, ubiquinone or coenzyme Q, is a fat soluble substance. Coenzyme Q10 is an electron shuttling compound that is critical to the electron transport chain (ETC). The ETC drives ATP synthesis which is a vital source of energy for the cell. Vitamin E, also known as α -tocopherol, is an important component of membranes (including mitochondrial membranes) and functions to scavenge lipid free radicals.

[0094] α -Lipoic acid, also known as thioctic acid is an organosulfur compound derived from octanoic acid which is an essential cofactor for mitochondrial dehydrogenases such as pyruvate dehydrogenase for proper function of the Krebs cycle ultimately resulting in ATP production. α -Lipoic acid also has direct skeletal muscle effects by activating AMPK, an energy sensor in the cell that regulates mitochondrial biogenesis via PGC1 α .

[0095] Polyphenols include phenolic acid and flavonoids. For example phenolic acids include protocatechuic acid, gallic acid, hydroxybenzoic acid, hydroxycinnamic acid such as caffeic acid, chlorogenic acid, coumaric acid, ferulic acid, sinapic acid, anthocyanins such as cyanidin, pelargonidin, peonidin, delphinidin and malvidin.

- 5 Exemplary flavonoids include flavonols such as quercetin, kaempferol, myricetin, flavones such as apigenin and luteolin, glavaonones such as hesperetin, naringenin, and eriodictyol, isoflavones such as daidzein, genistein, and glycitein, and monomeric flavonols such as catechin and epicatechin.

Administration and Dosing

- 10 [0096] The present disclosure provides materials and methods for the treatment of muscular dystrophy and chronic muscle wasting using at least one, antioxidant. Exemplary compositions and methods of treating muscular dystrophy comprising administering at least one antioxidant, or administering at least two antioxidants or administering at least three antioxidants. For example, the invention provides
- 15 antioxidant compositions comprising α -lipoic acid, coenzyme Q10 and α -tocopherol (also known as vitamin E). In some embodiments, the antioxidant composition disclosed herein may be administered alone or in combination with AAV vectors comprising a nucleotide sequence encoding the ANO5 protein or a functionally active fragment thereof.
- 20 [0097] Methods of the present disclosure are performed using any medically-accepted means for administering the agents directly or indirectly into a mammalian subject, including but not limited to injections, oral ingestion, intranasal, topical, transdermal, parenteral, inhalation spray, vaginal, or rectal administration. The term parenteral as used herein includes subcutaneous, intravenous, intramuscular, and
- 25 intracisternal injections, as well as catheter or infusion techniques. Administration by, intradermal, intraperitoneal, intrathecal, retrobulbar, intrapulmonary injection and or surgical implantation at a particular site is contemplated as well.

- [0098] In one embodiment, administration is performed at the affected tissue (e.g. muscle) needing treatment by direct injection into the site or via a sustained delivery
- 30 or sustained release mechanism, which can deliver the formulation internally. For example, biodegradable microspheres or capsules or other biodegradable polymer configurations capable of sustained delivery of a composition (e.g., a soluble

polypeptide, antibody, or small molecule) can be included in the formulations of the disclosure implanted near or at affected tissue.

[0099] In some embodiments, concurrent administration of antioxidants and AAV vectors comprising ANO5 does not require that the agents be administered at the same time or by the same route, as long as there is an overlap in the time period during which the agents are exerting their therapeutic effect. Simultaneous or sequential administration is contemplated, as is administration on different days or weeks.

[00100] In some embodiments, antioxidants and/or AAV vector compositions may also be delivered to the patient at multiple sites. The multiple administrations may be rendered simultaneously or may be administered over a period of time. In certain cases it is beneficial to provide a continuous flow of the therapeutic composition. Additional therapy may be administered on a period basis, for example, hourly, daily, every other day, twice weekly, three times weekly, weekly, every 2 weeks, every 3 weeks, monthly, or at a longer interval.

[00101] It is contemplated the agents of the present disclosure may be given simultaneously, in the same formulation. It is further contemplated that the agents are administered in a separate formulation and administered concurrently, with concurrently referring to agents given within 30 minutes of each other.

[00102] Thus, the invention provides methods of administering an effective dose (or doses, administered essentially simultaneously or doses given at intervals) of rAAV that encode, for example, ANO5 and/or antioxidants to a patient in need thereof.

[00103] The amounts antioxidants compositions in a given dosage may vary according to the size of the individual to whom the therapy is being administered as well as the characteristics of the disorder being treated. In exemplary treatments, it may be necessary to administer an antioxidant diet comprising about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0% lipoic acid, about 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0% coenzyme Q10 and about 10, 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000 IU α -tocopherol or vitamin E. These concentrations may be administered as a single

dosage form or as multiple doses. Standard dose-response studies, first in animal models and then in clinical testing, reveals optimal dosages for particular disease states and patient populations.

[00104] It will also be apparent that dosing may be modified if traditional
5 therapeutics are administered in combination with therapeutics of the disclosure.

EXAMPLES

Example 1

Isolation and Generation of an *Ano5*^{-/-} mouse model

[00105] An *Ano5* knock-out model was generated using a vector targeting *Ano5*
10 from exon 8 to exon 9 to produce a truncated transcript as shown in Fig. 1A. The targeting construct was designed as a “knock-out first” conditional ready construct so that a null allele is generated through splicing to a *lacZ* trapping element as described Tesla *et al.* (*Genesis* 38, 151-158 (2004)). This *lacZ*-tagged mutant allele *Ano5*:tm1a(KOMP)Wtsi targeting vector was obtained from the UC Davis KOMP
15 Repository (PG00097_Z_1_G0; Karnes. *Nature* 474, 337-342 (2011)). The targeting cassette was inserted following exon 8 with flanking FRT and loxP sites present to generate a conditional allele if embryonic lethality was noted.

[00106] Following embryonic stem cell targeting and transfer, the genotypes were verified by genomic PCR (Fig. 1b). Clones were screened by RT-PCR using the
20 following primer sets spanning exons 1-6 (e1-6) or exons 17-20 (e17-20), which produced a 300bp amplicon from the endogenous *Ano5* locus and a 200bp amplicon from the *Ano5* cassette insertion locus, as shown in Fig. 1c:

genotyping F 5'-AGTCCTTTTCAGCACAGTCTTTG-3' (SEQ ID NO: 3)
genotyping R 5'-TGAGGCAGTGTGGAGTGAGTA-3' (SEQ ID NO: 4)
25 DF38700 5'-GCCAATCATATGGTCTCAGT-3' (SEQ ID NO: 5)
LR-loxp R 5'-ACTGATGGCGAGCTCAGACC-3' (SEQ ID NO: 6)

[00107] Successfully targeted ES cells were then injected into blastocysts of C57BL/6 mice, and embryos transferred to generate chimeras for germline transmission. Transgenic heterozygotes were verified by genotyping and were
30 backcrossed four times to C57BL/6 wild type, before breeding to homozygosity. Stocks of *Ano5*^{-/-} and C57BL/6 mice were bred and maintained as homozygous

animals in standardized conditions in the Vivarium at the RINCH. They were maintained on Teklad Global Rodent Diet (3.8% Fiber, 18.8% Protein, 5% fat chow) with a 12:12 h dark:light cycle.

[00108] Quantitative PCR was performed and analyzed on a Fast Real-Time PCR System (Thermo Fisher Scientific). Reactions were run with Applied Biosystems primer-FAM probe cocktails for *Ano5* (Mm00624629_m1, Mm01335981_m1), *Ano6* (Mm00614693_m1), and *Gapdh* (Mm99999915_g1), in triplicate for each sample. The $\Delta\Delta C_t$ method was used to calculate normalized fold-change reductions of *Ano5* and *Ano6* mRNA in *Ano5*^{-/-} muscles as compared to wild type. Total RNA was isolated from fresh-frozen muscle shavings using Trizol (Life Technologies, Carlsbad, CA), according to the manufacturer's protocol. RNA was then column-purified using the RNeasy method (Qiagen, Valencia, CA), and quantified by spectrophotometry using a NanoDropLite (Thermo Fisher Scientific, Waltham, MA). cDNA was generated with the High Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientific), using equivalent amounts of sample RNA per reaction (200-500 ng). For semi-quantitative PCR, equal volumes of cDNA were subjected to 30 PCR cycles, followed by agarose gel electrophoresis. Primers used were:

m β Act-rt-5' CCTGGCCGTCAGGCAGAT (SEQ ID NO: 7)
 m β Act-rt-3' GACATGGAGAAGATCTGGCACC (SEQ ID NO: 8)
 mAno5-rt-F1 CCAACAGAATGAGAACCT (SEQ ID NO: 9)
 mAno5-rt-R1 GACAGGGGTGGGTACTTTGG (SEQ ID NO: 10)
 mAno5-rt-F3 CGTTGGCAGCAAGATCAT (SEQ ID NO: 11)
 mAno5-rt-R3 GGGTACCTATAATCTCTGTACCTGC (SEQ ID NO: 12)

[00109] Quantitative RT-PCR demonstrated ~80% reduction in pre-cassette transcript and >99% reduction of post-cassette ANO5 transcript in all muscles tested (**Fig. 1d**). No embryonic lethality or difficulty breeding was noted. As *Ano5* shares a significant sequence homology to *Ano6*, and *Ano6* is known to be expressed in skeletal muscle under some conditions, RT-PCR was performed to measure relative expression of ANO6 cDNA of *Ano5*^{-/-} mouse muscles. Quantitative RT-PCR demonstrates a modest, but statistically insignificant elevation of *Ano6* transcript in *Ano5* deficient muscles.

Example 2

Clinical and histopathological evaluation of the *Ano5*^{-/-} mouse

[00110] The *Ano5*^{-/-} mouse exhibited many features characteristic of human *ANO5*-myopathy including increased serum creatine kinase levels, variable weakness among
5 muscles, altered muscle fiber diameter, and exercise intolerance. Serum creatine kinase is elevated approximately 2-fold in *Ano5*^{-/-} mice (**Fig. 2a**).

[00111] Tetanic force measurements were obtained from extensor digitorum longus (EDL) of 10 month old mice (n=6 mice per strain), tibialis anterior (TA) from 4 month old mice (n=5 mice per strain), and diaphragm muscles of 10 month old *Ano5*^{-/-}
10 and WT mice (n=4 mice per strain). The EDLs were dissected at the tendons and subjected to a physiology protocol to assess function as previously described by Rodino-Klapac *et al.* (J. Transl. Med. 5: 45, 2007) and Liu *et al.* (Mol. Ther. 11:245-256, 2005) with modifications. During the eccentric contraction protocol, a 5% stretch-re-lengthening procedure executed between 500 and 700 ms (5% stretch over
15 100 ms, followed by return to optimal length in 100 ms). Following the tetanus and eccentric contraction protocol, the mice were then euthanized and the muscle was dissected, wet-weighted, mounted on chuck using gum tragacanth, and then frozen in methyl-butane cooled in liquid nitrogen. Force measurements in the TA were performed as described by Hakim *et al.* (J. Appl. Physiol. 110: 1656-1663, 2011) and
20 Wein *et al.* (Nat. Med. 20:992-1000, 2014).

[00112] For diaphragm force measurements, mice were euthanized and the diaphragm was dissected with rib attachments and central tendon intact, and placed in Krebs-Henselet (K-H) buffer as previously described by Beastron *et al.* (Am. J. Pathol. 179: 2464-2474, 2011), Rafeal-Fortney *et al.* (Circ. 124: 582-588, 2011) and
25 Grose *et al.* (Ann. Clin. Trans. Neurol. 1: 34-44, 2014). A 2-4 mm wide section of diaphragm was isolated. Diaphragm strips were tied firmly with braided surgical silk (6/0; Surgical Specialties, Reading, PA) at the central tendon, and sutured through a portion of rib bone affixed to the distal end of the strip. Each muscle was transferred to a water bath filled with oxygenated K-H solution that was maintained at 37°C. The
30 muscles were aligned horizontally and tied directly between a fixed pin and a dual-mode force transducer-servomotor (305C; Aurora Scientific, Aurora, Ontario, Canada). Two platinum plate electrodes were positioned in the organ bath so as to

flank the length of the muscle. The muscle was stretched to optimal tension of 1 g, and then allowed to rest for 10 minutes before initiation of the tetanic protocol. Once the muscle was stabilized, the muscle was subjected to a warm-up consisting of three 1 Hz twitches every 30 seconds followed by three 150 Hz twitches every minute.

- 5 After a 3 minute rest period, the diaphragm was stimulated at 20, 50, 80, 120, 150, 180 Hz, allowing a 2 minute rest period between each stimulus, each with a duration of 250 ms to determine maximum tetanic force. Muscle length and weight was measured. The force was normalized for muscle weight and length (CSA: muscle mass (mg)/{Lf(mm) x muscle density (1.06mg/mm³)}). Statistical significance was assessed using an unpaired Student's T-test for specific force and 2-way ANOVA with repeated measurements for resistance to eccentric contraction protocol.

- [00113]** The specific force of muscle contraction was significantly decreased ~15% in diaphragm (**Fig. 2b**), but was essentially unaffected in extensor digitorum longus (EDL) and tibialis anterior (TA) muscles (**Fig. 2c**) of the *Ano5^{-/-}* mice. This
- 15 variability among muscles is characteristic of *ANO5* myopathies and was also observed in histological analysis of different muscles. Relative to wild type (WT), average muscle fiber diameter was significantly smaller in gastrocnemius (GAS) muscle from *Ano5^{-/-}* mice (*Ano5^{-/-}* 35.8 ± 8.3 μm, WT: 41.8 ± 11.0 μm, P<0.001), and to a lesser extent in the TA muscle (*Ano5^{-/-}* 38.1 ± 11.8 μm, WT: 44.3 ± 12.2 μm, P<0.001) (**Fig. 2d,e**). *Ano5^{-/-}* muscles exhibited mild histopathology including central nuclei and occasional necrotic fibers (**Fig. 2d,e**).

- [00114]** To evaluate exercise tolerance, 7.5 month old aged-matched *Ano5^{-/-}* and WT mice were subjected to exercise regimes weekly for 1 hour for 2 months. Each mouse was run once a week at a -10° decline with a speed of 15 m/min and increased
- 25 by 1 m every minute until exhaustion was reached (n=3 mice per strain). Each individual test was stopped when the mouse remained on the shock plate (Columbus Instruments) with electrical stimulus set to 20V for more than 10 seconds without attempting to engage in exercise. Breaks were defined as the times where the mice ceased running and rested while the treadmill belt returned to the shock plate. While
 - 30 WT control mice ran at a consistent speed with no breaks, *Ano5^{-/-}* mice were prone to frequent breaks on the treadmill (14 pauses/min) where they ceased running until the treadmill belt returned to the shock plate (**Fig. 2f**).

[00115] Electrophysiology was performed on 6-8 mo *Ano5*^{-/-} and control muscles using methods similar to those described in Arnold *et al.* (*Ann. Clin. Trans. Neurol.* 1:34-44, 2014). Mice were anesthetized using inhaled isoflurane and placed in the prone position with the hind limbs extended at 45° away from the body of the animal.

5 Compound muscle action potential (CMAP) amplitudes were measured from bilateral triceps surae muscles following supramaximal sciatic nerve stimulation in mutant (n=6 animals, 12 hind limbs) and control (n=7 animals, 14 hind limbs) mice. Needle electromyography was performed in the right GAS muscle to assess for the presence or absence of fibrillation potentials. Localized impedance measures, or electrical

10 impedance myography (EIM), was performed in bilateral GAS muscles at frequencies from 1000 Hz-10 MHz using a Skulpt Inc EIM1103 system (San Francisco, CA) using methods similar to those previously reported in mouse models of amyotrophic lateral sclerosis and muscular dystrophy (Li *et al.* *PLoS One* 8:e65976, 2013; Li *et al.* *Muscle & Nerve* 49: 829-835, 2014). A fixed electrode array with four 26 gauge

15 insulated electromyography needle electrodes (Natus, Middleton, WI) spaced 1 mm apart was used in place of surface electrodes. The electrode array was inserted into the belly of bilateral gastrocnemius muscles in a longitudinal configuration in respect to muscle fiber direction, and two trials of impedance measurements were obtained in each muscle and averaged for a single value in each limb (n=6 animals, 12 hind limbs

20 for each group). Using the convention from previously published EIM studies and for simplicity, reactance, resistance, and phase was analyzed at two current frequencies, 50 kHz and 100 kHz. CMAP amplitudes and impedance characteristics were compared using a two-tailed t test. Needle electromyography, evoked compound muscle action potential recordings, and electrical impedance myography were

25 performed in the hindlimbs of *Ano5*^{-/-} and WT mice but showed no significant changes, similar to the human disease (Fig. 3).

[00116] Another characteristic feature of human *ANO5* myopathy is the presence of an excessive number of muscle fibers with intramuscular deposits. Muscle cross-sectional fiber diameters were determined from TA and gastrocnemius (GAS)

30 muscles from 6 month old *Ano5*^{-/-} and WT strain control mice (n=3 mice per strain). Muscles were sectioned and stained with hematoxylin and eosin (H&E). 4 random 20x images per section per animal were taken with a Zeiss AxioCam MRC5 camera.

Fiber diameters were determined by measuring the shortest distance across the muscle fiber using Zeiss Axiovision LE4 software. Fiber diameter histograms were generated from an average of 500-600 fibers per TA and 600-700 fibers per GAS. An unpaired t-test was used to test significant differences between *Ano5*^{-/-} and WT fiber sizes

5 (****p<0.0001).

[00117] Aggregates within the muscles were quantitated. Muscle sections from TA and GAS muscles of 10 month old *Ano5*^{-/-} and WT mice (n=3 mice per tissue and strain) were stained with Gomori Trichrome. Four 20X images were taken and the number of fibers with one or more aggregates were counted using Image J software and expressed as a percentage of the total number of fibers. Using GraphPad Prism, a one-way ANOVA was used to test significance between *Ano5*^{-/-} and WT fibers

10 (****p<0.0001).

[00118] In addition, succinate dehydrogenase staining (*SDH*) was carried out on the aggregates and muscle: Tibialis anterior (TA) and quadriceps muscles were

15 sectioned at 18 µm and stained with SDH solution consisting of 0.2% nitro blue tetrazolium (NBT) dissolved in 0.1 M succinic acid and 0.1 M phosphate buffer pH 7.4 and incubated at 37°C for 3 hrs. Following incubation, slides were rinsed with water and dehydrated in serial alcohols then cleared with xylene. Slides were imaged on Zeiss AxioCam MRC5 camera.

[00119] Segments of TA muscle from 4 and 10 month old *Ano5*^{-/-} and control mice were removed, stretched to their in situ length across a wooden tongue depressor and immersed in 3% glutaraldehyde in 0.1 M phosphate buffer pH 7.0 for 4 hours. The muscle was dissected into 2-mm-long tissue blocks, stored in 0.1 M phosphate buffer pH 7.4 overnight, followed by post-fixation in 1% osmium tetroxide for 2 hours and

25 dehydration in graded ethanol solutions before plastic embedding. 1 µm-thick cross sections were stained with toluidine blue, examined by light microscopy, and tissue sections from selected blocks were examined under a Hitachi H-7650 TEM electron microscope utilizing an Advanced Microscopy Techniques camera and software.

[00120] In the *Ano5*^{-/-} mouse muscle, these structures appear as sharply-defined, irregularly-contoured areas that stain red with a modified trichrome stain as described in Pavlocicova *et al.* (*Gen. Physiol. Biophysics* 22: 425-440, 2003).

30 Cytoplasmic aggregates were apparent beginning at 9 months of age and increased

over time (**Fig. 4a**). Because aggregates of similar appearance have been noted in normal aged mice, aggregate occurrence was quantified. Approximately 25% of *Ano5*^{-/-} fibers displayed irregularly-contoured red areas upon trichrome staining, while <0.02% of control fibers had these aggregates (**Fig. 4b**). Electron microscopy (EM) revealed that these aggregates were comprised of membranous material. Many *Ano5*^{-/-} muscle fibers exhibited densely packed accumulations of vesicular or tubular membranes or haphazardly oriented and loosely packed interconnecting tubular formations with fuzzy inner tubules that corresponded to the aggregates seen in light microscopy (**Fig. 4c,d**). *ANO5*^{-/-} mice showed similar pathology findings consistent with that of diagnosed *ANO5* patients. Electron microscopy of patient muscle with compound heterozygous for two mutations [c.155A>G (p.Asn52Ser)] + [c.191dupA (p.Asn64Lysfs*15)] in the coding region of the *ANO5* gene revealed numerous aggregates and multiple sites displaying areas of degenerating mitochondria. Aggregates in *Ano5*^{-/-} muscle stained positive for SERCA1 but not for succinate dehydrogenase (SDH) activity, suggesting that they are derived from the sarcoplasmic reticulum and not from mitochondria (**Fig. 4g**). However, *Ano5*^{-/-} mice did exhibit degenerating mitochondria and sub-sarcolemmal mitochondrial accumulation in addition to these membrane aggregates (**Fig. 4e**). The sub-sarcolemmal accumulation of mitochondria was confirmed by staining frozen sections for SDH, which was localized in dense patches near the surface of muscle fibers (**Fig. 4f**). To identify whether the mitochondrial degeneration observed had functional significance, citrate synthase activity was quantified as a measure of intact mitochondria and demonstrated that there was a significant decrease in *Ano5*^{-/-} muscle extracts compared to WT controls

25

Example 3

Ano5 facilitates membrane repair

[00121] In healthy individuals, normal exercise results in small lesions in the plasma membrane that are healed by two processes: (i) small tears are resealed by assembly of new plasma membrane and (ii) sites of more severe disruption are repaired by satellite cells that differentiate into myoblast-like cells and fuse to regenerate multinucleated muscle fibers. To test the effect of loss of *ANO5* expression on membrane repair, the effect of membrane damage produced by an

30

intense laser pulse delivered to isolated flexor digitorum brevis (FDB) muscle fibers was examined. 12 μ m cryosections were placed onto Fisher Superfrost microscope slides and blocked with 10% goat serum and 0.1% Tween-20 in PBS for 1 hour at room temperature. Slides were incubated in primary antibody for 1 hour at room temperature (Anti-FLAG F7425 Sigma-Aldrich, 1:175), Serca1 CaF2-5D2 (Developmental Studies Hybridoma Bank, 1:50). Slides were then rinsed 3 times with PBS for 1 hour at room temperature followed by a 30 min block. Goat-anti-mouse conjugated to Alexa Fluor 594 (A21125, Life Technologies) or goat-anti-rabbit conjugated to Alexa Fluor 568 (A11011, Life Technologies) secondary antibodies were diluted at 1:250 in blocking solution and incubated for 45 min followed by 3 PBS rinses for 1 hour. The sections were mounted with Vectashield (Vector Labs, Burlingame, CA) mounting media and analyzed with a Zeiss Axioskop 2 microscope using a Cy5 filter (excitation, 578 nm-590 nm; emission 603 nm-671 nm) (Zeiss, Thornwood, NY). Image exposure time was standardized using the positive control for each antibody, each day. Images were taken using the Axiovision 4.5 software.

[00122] Membrane damage was assessed by accumulation of FM1-43, a membrane-impermeant styryl cationic dye that is not fluorescent in aqueous solution but fluoresces brightly in a lipid environment and has been used extensively to study membrane repair. A small area of fluorescence was detected at the site of damage in WT and *Ano5*^{-/-} fibers immediately after laser injury (**Fig. 5a**). The increase in fluorescence was greater and occurred at a ~2-fold faster initial rate in *Ano5*^{-/-} muscle fibers than in WT fibers. Whereas the fluorescence appeared to be leveling off at 190 sec in WT, the fluorescence continued to increase in *Ano5*^{-/-} fibers for the duration of the experiment (**Fig. 5b**).

[00123] To test whether the defect in membrane repair was directly related to ANO5 expression, the human ANO5 cDNA was expressed using adeno-associated virus (AAV) in the *Ano5*^{-/-} muscles (Fig. 4b,c). The human ANO5 cDNA (SEQ ID NO: 1) was cloned into an AAV2 ITR plasmid using Not1 restriction sites between the MHCK7 promoter and polyadenylation signal. rAAV vectors were produced by a modified cross-packaging approach whereby the AAV type 2 ITRs can be packaged into multiple AAV capsid serotypes as described in Rabinowitz *et al.* (*J. Virol.* 76: 791-801, 2000). Production was accomplished using a standard 3-plasmid DNA

CaPO₄ precipitation method using HEK293 cells. HEK293 cells were maintained in DMEM supplemented with 10% Cosmic calf serum (CCS, Hyclone). The production plasmids were: (i) pAAV.MHCK7.ANO5, (ii) rep2-cap8 modified AAV helper plasmids encoding cap serotype 8-like isolate rh.74, and (iii) an adenovirus type 5 helper plasmid (pAdhelper) expressing adenovirus E2A, E4 ORF6, and VA I/II RNA genes. Vectors were purified from clarified HEK293 cell lysates by sequential iodixanol gradient purification and anion-exchange column chromatography using a linear NaCl salt gradient as previously described in Clark *et al.* (*Human Gene Ther.* 10: 1031-10398, 1999). A quantitative PCR-based titration method was used to determine an encapsidated vector genome (vg) titer utilizing a Prism 7500 Taqman detector system (PE Applied Biosystems, Carlsbad, CA).

[00124] AAV vector delivery through intramuscular injection to mouse muscle. Four-five week old *Ano5*^{-/-} mice were treated by intramuscular injection of 1x10¹¹ vg of rAAVrh.74.MHCK7.huANO5.FLAG into TA (n=4) or FDB (n=4) muscles. TA muscles were harvested 4 weeks post injection and processed for histological and immunofluorescent examination.

[00125] Flexor digitorum brevis (FDB) muscle fibers were harvested 10 weeks post treatment and subjected to a laser-induced injury. Membrane repair assay was performed on left and right FDB muscles of *Ano5*^{-/-} (n=4) and age-matched C57BL6 (n=4) mice as described by Sondergaard et al. (*Ann. Clin. Trans. Neurol.* 2:256-270, 2015). Briefly, FDB fibers were isolated using a solution containing 2% w/v collagenase type I suspended in DMEM. Following dissociation of the muscle, fibers were placed in a glass bottom dish holding 2.5 μM FM1-43 dye in Dulbecco's PBS (no Ca/Mg) supplemented with 1.5 mM Ca²⁺. Fibers were subjected to laser injury using a FluoView® FV1000 two-photon confocal laser-scanning microscope (Olympus). Fibers were damaged with an 850 nm laser-guided spot of 4.479 mm at 20% power and imaged every 5 sec for 190 s to visualize FM1-43 dye uptake. An average of 7-10 fibers were imaged per muscle per mouse, (total 31 WT, 39 *Ano5*^{-/-}, and 30 AAV-ANO5 rescued *Ano5*^{-/-} fibers). Fluorescence intensity of dye infiltration surrounding the damage site on the membrane was analyzed with Image J software by measuring integrated density of pixel intensity within the defined area. To do so, under a 2X zoom setting on ImageJ, a rectangular box measuring 0.75 pixels by 1.00

pixel is drawn and used to measure the intensity of dye in that region. In the analysis, measured fluorescent intensity at an individual time point was normalized to initial intensity measured at $t=-5s$ (pre-injury). When fluorescence intensity was analyzed, values from all fibers from each strain were averaged together. A 2-way ANOVA was performed to determine statistical significance between treated and untreated fibers at each time point ($p<0.001$). To quantify the change in fluorescence, the data points were fit to the Hill equation using Origin Pro 9.1. All curves were fit with adjusted $R^2 > 0.998$. *Ano5*^{-/-} fibers, WT fibers, and AAV.ANO5 treated *Ano5*^{-/-} fibers were significantly different beginning at 100 seconds post-injury. AAV.ANO5 partially restored membrane resealing in *Ano5*^{-/-} muscle (**Fig. 5a,b,c**).

Example 4

Impaired Regeneration in *Ano5* KO mice

[00126] Investigation of whether muscle regeneration was also defective in *Ano5*^{-/-} mice was carried out by examining the ability of the muscle to recover from injury produced by cardiotoxin injection (**Fig. 5d**). Mice were anesthetized with inhaled isoflurane and injected with cardiotoxin (diluted to 10 μM with sterile saline) every two weeks, for a total of 3 rounds. 30 μL and 50 μL of cardiotoxin was injected into the left TA and left GAS muscles respectively of 8 week old *Ano5*^{-/-} and aged-matched controls. Sterile saline was injected into contralateral muscle as a sham control. Groups of mice were euthanized and their muscles harvested at 1, 3, 7 and 14, 30 and 90 days post final injection of cardiotoxin ($n=3$ mice per strain per timepoint). Four 20X images per TA were imaged and fiber diameter was measured on H&E-stained cryosections 1 and 3 months after the final cardiotoxin injection using Axio Vision 4.8. An average of 500-600 muscle fibers were measured and an unpaired t-test was performed (GraphPad Prism) to determine statistical significance between muscle fiber size of injured *Ano5*^{-/-} mice and injured control mice (**** $p<0.0001$).

[00127] To track temporal changes of necrosis and regeneration, TA and GAS muscles of 8 week-old mice were injected with cardiotoxin 3 times spaced 2 weeks apart. Tissues were harvested 1, 3, 7, 14, 30, and 90 d after the final injection (**Fig. 5d**). The contralateral side was used as a saline-only control. The WT muscle regenerated after cardiotoxin treatment, so that by 1 month the muscle appeared largely normal with the exception of central nuclei in newly regenerated fibers.

However, in *Ano5*^{-/-} mice, there was an extensive delay in regeneration and longstanding necrosis. After 3 months, the mean fiber diameter of *Ano5*^{-/-} muscle remained significantly reduced compared to WT and many fibers exhibited central nuclei (**Fig. 5d,e**).

5

Example 5

Assessing the effect of antioxidant therapy

[00128] To examine the potential benefits of a triple antioxidant diet on the skeletal muscle of Anoctamin 5 deficient (*Ano5*^{-/-}) mice, cohorts of 2 month old wild type (WT) BL6 mice and *Ano5*^{-/-} mice were fed either normal mouse chow or a diet
10 supplemented with a triple antioxidant composition comprising 1000 IU vitamin E, 0.1% α -lipoic acid, and 0.25% coenzyme Q10 (in reduced ubiquinol form). Mice were run to exhaustion for 3 consecutive days every 4th week for a period of 16 weeks, and sacrificed to examine functional outcome measures associated with muscle health (activity and diaphragm force) and oxidative stress (citrate synthase
15 activity and pgc1 α expression).

Laser Monitoring of Open Field Cage Activity

[00129] An open-field activity chamber was used to determine overall activity of experimental mice following a previously described protocol (Kobayashi *et al.*, *Nature* 456: 511-5 (2008); Beastron *et al.*, *Am J Pathol* 179: 2464-74 (2011)) with
20 several modifications. All mice were tested at the same time of day in the early morning near then end of the night cycle when mice are most active. All mice were tested in an isolated room, under dim light and with the same handler each time. Also, as was done in the previous reports to reduce anxiety and keep behavioral variables at a minimum, which could potentially affect normal activity of the mice
25 and consequently the results of the assay, we tested mice that were not individually housed (Voikar *et al.*, *Genes Brain Behav* 4: 240-52(2005)). Mice were activity monitored using the Photobeam Activity System (San Diego Instruments, San Diego, CA). This system uses a grid of invisible infrared light beams that traverse the animal chamber front to back and left to right to monitor the position and movement of the
30 mouse within an X-Y-Z plane. Activity was recorded for 1 hour cycles at 5-minute intervals. Mice were acclimatized to the activity test room for an initial 1 hour

session several days prior to beginning data acquisition. Mice were tested in individual chambers in sets of 4. Testing equipment was cleaned between each use to reduce mouse reactionary behavioral variables that could alter our results. Data collected was converted to a Microsoft Excel worksheet and all calculations were done within the Excel program. Individual beam breaks for movement in the X and Y planes were added up for each mouse to represent total ambulation, and beam breaks in the Z plane were added up to obtain vertical activity within the 1 hour time interval.

[00130] At the end of weeks 12 and 16, two mice from each group were placed in an activity cage to monitor voluntary activity. Total mouse activity was measured as the number of times mice broke horizontal and/or vertical laser beams in a 45 minute period following treadmill exhaustion (**Fig. 6**). *Ano5^{-/-}* mice receiving the antioxidant diet were found to be more active than those on a standard (placebo) diet at 16 weeks, suggesting that the antioxidants had a positive effect on voluntary activity following exhaustion.

15 ***Diaphragm Tetanic Contraction for Functional Assessment***

[00131] While behavioral assays were suggestive of some treatment effect, these outcome measures are subject to several variables independent of diet. To examine impact of antioxidant supplementation on skeletal muscle function, force measurements were performed on the diaphragm of mice *Ano5^{-/-}* and WT mice (**Fig. 7**). The diaphragm was chosen because it was previously demonstrated that *Ano5^{-/-}* mice have a deficit in diaphragm force, but not in limb muscles (Griffin *et al.*, *Hum Mol Genet* **25**: 1900-1911 (2016)).

[00132] Mice were euthanized and the diaphragm was dissected with rib attachments and central tendon intact, and placed in K-H buffer as previously described (Beastrom *et al.*, *Am J Pathol* 179: 2464-74 (2011); Rafael-Fortney *et al.*, *Circulation* 124: 582-8 (2011); Moorwood *et al.*, *Journal of Visualized Experiments* 71: e50036 (2013)). A 2-4 mm wide section of diaphragm was isolated. Diaphragm strips were tied firmly with braided surgical silk (6/0; Surgical Specialties, Reading, PA) at the central tendon, and sutured through a portion of rib bone affixed to the distal end of the strip. Each muscle was transferred to a water bath filled with oxygenated K-H solution that was maintained at 37°C. The muscles were aligned horizontally and tied directly between a fixed pin and a dual-mode force transducer-

servomotor (305C; Aurora Scientific, Aurora, Ontario, Canada). Two platinum plate electrodes were positioned in the organ bath so as to flank the length of the muscle. The muscle was stretched to optimal length for measurement of twitch contractions, and then allowed to rest for 10 minutes before initiation of the tetanic protocol. Once

5 the muscle was stabilized, the muscle was set to an optimal length of 1g and is subjected to a warm-up which consists of three 1Hz twitches every 30 seconds followed by three 150Hz twitches every minute. After a 3 min rest period, the diaphragm was stimulated at 20, 50, 80, 120, 150, 180Hz, allowing a 2 min rest period between each stimulus, each with a duration of 250ms to determine maximum

10 tetanic force. Muscle length and weight was measured. The force was normalized for muscle weight and length. A significant improvement in diaphragm specific force was observed in triple antioxidant-treated *ano5^{-/-}* mice compared to placebo-treated *ano5^{-/-}* mice (**Fig. 7**).

Mitochondrial Biogenesis

15 **[00133]** Having established a connection with triple antioxidant therapy and oxidative fiber content, mitochondrial biogenesis and function was analyzed. Previous studies have shown exercise to stimulate pathways leading to mitochondrial biogenesis, while antioxidant therapy decreases this signaling. Results on male gastrocnemius muscle tissue confirmed that antioxidant treatment reduced expression

20 of the key regulator of mitochondrial biogenesis PGC-1 α (**Fig. 8a**). Interestingly, citrate synthase activity was found to be higher in antioxidant-fed mice among all genotype-gender combinations (**Fig. 8b**). One simple explanation for this is that the increased proportion of oxidative fibers, which are high in mitochondrial content, masks any decrease in mitochondrial biogenesis per fiber.

25 **[00134]** In summary, triple antioxidant therapy was found to have a significant impact on some measures of muscle physiology & function, including voluntary activity, diaphragm strength, fiber size, fiber type composition, and mitochondrial enzyme activity. These results were found to be, in certain cases, gender specific. LGMD2L is gender specific with males more severely affected.

CLAIMS

What is claimed:

1. A method of treating muscular dystrophy comprising administering a therapeutically effective amount of recombinant AAV vector comprising 1) a nucleic acid sequence that is at least 85% identical to the nucleic acid sequence of SEQ ID NO:1, 2) a nucleotide that hybridizes under stringent condition to the nucleotide sequence of SEQ ID NO: 1 or 3) a fragment of nucleic acid of SEQ ID NO: 1 encoding a protein that exhibits ANO5 activity to a subject in need thereof.
2. A method of regenerating muscle in a subject in need comprising administering a recombinant AAV vector comprising 1) a nucleic acid sequence that is at least 85% identical to the nucleic acid sequence of SEQ ID NO:1, 2) a nucleotide that hybridizes under stringent condition to the nucleotide sequence of SEQ ID NO: 1, or 3) a fragment of nucleic acid of SEQ ID NO: 1 encoding a protein that exhibits ANO5 activity to the subject in an amount effective to regenerate muscle.
3. A method of treating chronic muscle wasting comprising administering a therapeutically effective amount of recombinant AAV vector comprising 1) a nucleic acid sequence is at least 85% identical to the SEQ ID NO:1, 2) a nucleotide that hybridizes under stringent condition to the nucleotide sequence of SEQ ID NO: 1 or 3) a fragment of nucleic acid of SEQ ID NO: 1 encoding a protein that exhibits ANO5 activity to a subject in need thereof.
4. The method of any one of claims 1-3 wherein the recombinant AAV comprises a polynucleotide sequence of SEQ ID NO: 1.
5. The method of any one of claims 1-4 wherein the recombinant AAV vector of is AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13 or AAV rh.74.
6. The method of any one of claims 1-5 wherein the recombinant AAV vector comprises a polynucleotide operably linked to a muscle-specific control element.
7. The method of claim 6 wherein the muscle-specific control element is human skeletal actin gene element, cardiac actin gene element, myocyte-specific enhancer

binding factor MEF, murine creatine kinase enhancer element, skeletal fast-twitch troponin C gene element, slow-twitch cardiac troponin C gene element, the slow-twitch troponin I gene element, hypoxia-inducible nuclear factors, steroid-inducible element or glucocorticoid response element (GRE).

- 5 8. The method of any one of claims 2-7 wherein the subject is suffering from muscular dystrophy.
9. The method of any one of claims 1-8 wherein the muscular dystrophy is dysferlin-associated muscular dystrophy, limb girdle muscular dystrophy type 2L, or Miyoshi myopathy type 3, Bethlem myopathy, calpainopathy, desmin myopathy,
10 dysferlinopathy, myofibrillar myopathy, sarcoglycanopathy or ZASP-related myopathy.
10. The method of any one of claims 1-9 wherein the subject has a recessive mutation in the ANO5 gene.
11. The method of any one of claims 1-10 wherein the recombinant AAV vector is
15 administered by intramuscular or intravenous injection.
12. The method of any one of claims 1-11 further comprising the step of administering a therapeutically effective amount of an antioxidant composition to a subject in need thereof.
13. The method of claim 12 wherein the antioxidant composition comprises at
20 least one of a coenzyme Q10, lipoic acid, vitamin, carotenoid, vitamin cofactor, mineral, polyphenol, or flavonoid.
14. The method of claim 12 or 13 wherein the antioxidant composition comprises coenzyme Q10, lipoic acid and vitamin E.
15. A method of treating muscular dystrophy comprising administering a
25 therapeutically effective amount of an antioxidant composition to a subject in need thereof.

16. A method of treating chronic muscle wasting comprising administering a therapeutically effective amount of an antioxidant composition, to a subject in need thereof.
17. A method of slowing the progression of muscular dystrophy comprising
5 administering a therapeutically effective amount of an antioxidant composition, to a subject in need thereof.
18. A method of slowing the progression of chronic muscle wasting comprising administering a therapeutically effective amount of an antioxidant composition to a subject in need thereof.
- 10 19. The method of any one of claims 15-18 wherein the antioxidant composition comprises at least one of a coenzyme Q10, lipoic acid, vitamin, carotenoid, vitamin cofactor, mineral, polyphenol, or flavonoid.
20. The method of any one of claims 15-19 wherein the antioxidant composition comprises coenzyme Q10, lipoic acid and vitamin E.
- 15 21. The method of any one of claims 15-20 wherein muscular dystrophy is dysferlin-associated muscular dystrophy, limb girdle muscular dystrophy type 2L, or Miyoshi myopathy type 3, Bethlem myopathy, calpainopathy, desmin myopathy, dysferlinopathy, myofibrillar myopathy, sarcoglycanopathie or ZASP-related myopathy.
- 20 22. The method of any one of claims 15-21 wherein the oxidative stress is reduced in skeletal muscle of the subject.
23. The method of any one of claims 15-21 wherein the skeletal muscle function of the subject is improved.
24. The method of any one of claims 15-21 wherein the subject has a recessive
25 mutation in the ANO5 gene.
25. The method of any one of claims 12-25 wherein the antioxidant composition is administered orally.

26. The method of any one of claims 12-25 wherein the antioxidants are in the same composition.
27. The method of any one of claims 12-25 wherein the antioxidants are in separate compositions.
- 5 28. The methods of any one of claims 12-25 wherein the antioxidants of the antioxidant composition are administered concurrently.
29. The method of any one of claims 12-25 wherein the antioxidants of the antioxidant composition are administered at separate times or consecutively.
30. The method of any one of claims 12-29 wherein the antioxidant composition
10 is administered once daily, once weekly, twice weekly, once every two weeks, once every three weeks, monthly or once every two months.
31. A composition comprising a therapeutically effective amount of a recombinant AAV vector comprising 1) a nucleic acid sequence is at least 85% identical to the nucleic acid sequence of SEQ ID NO:1, 2) a nucleotide that hybridizes under stringent
15 condition to the nucleotide sequence of SEQ ID NO: 1 or 3) a fragment of nucleic acid of SEQ ID NO: 1 encoding a protein that exhibits ANO5 activity, for the treatment of muscular dystrophy in a subject in need.
32. A composition comprising a recombinant AAV vector comprising 1) a nucleic acid sequence is at least 85% identical to the SEQ ID NO:1, 2) a nucleotide that
20 hybridizes under stringent condition to the nucleotide sequence of SEQ ID NO: 1 or 3) a fragment of nucleic acid of SEQ ID NO: 1 encoding a protein that exhibits ANO5 activity to a subject in need thereof, for the regeneration of muscle in a subject in need.
33. A composition comprising a therapeutically effective amount of a recombinant
25 AAV vector comprising 1) a nucleic acid sequence is at least 85% identical to the nucleic acid sequence of SEQ ID NO:1, 2) a nucleotide that hybridizes under stringent condition to the nucleotide sequence of SEQ ID NO: 1, or 3) a fragment of nucleic acid of SEQ ID NO: 1 encoding a protein that exhibits ANO5 activity for the treatment of chronic muscle wasting in a subject in need.

34. The composition of any one of claims 31-33 wherein the recombinant AAV comprises a polynucleotide sequence of SEQ ID NO: 1.
35. The composition of any one of claims 31-34, wherein the recombinant AAV vector of is AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10,
5 AAV11, AAV12, AAV13 or AAV rh.74.
36. The composition of any one of claims 31-35 wherein the recombinant AAV vector comprises a polynucleotide operably linked to a muscle-specific control element.
37. The composition of claim 36 wherein the muscle-specific control element is
10 human skeletal actin gene element, cardiac actin gene element, myocyte-specific enhancer binding factor MEF, murine creatine kinase enhancer element, skeletal fast-twitch troponin C gene element, slow-twitch cardiac troponin C gene element, the slow-twitch troponin I gene element, hypoxia-inducible nuclear factors, steroid-inducible element or glucocorticoid response element (GRE).
- 15 38. The composition of any one of claims 31-37 wherein the subject is suffering from muscular dystrophy.
39. The composition of any one of claims 31-39 wherein the muscular dystrophy is dysferlin-associated muscular dystrophy, limb girdle muscular dystrophy type 2L, Miyoshi myopathy type 3, Bethlem myopathy, calpainopathy, desmin myopathy,
20 dysferlinopathy, myofibrillar myopathy, sarcoglycanopathy or ZASP-related myopathy.
40. The composition of any one of claims 31-39 wherein the subject has a recessive mutation in the ANO5 gene.
41. The composition of any one of claims 31-40 that is formulated for
25 intramuscular or intravenous injection.
42. The composition of any one of claims 31-41 further comprising a therapeutically effective amount of an antioxidant composition.

43. The composition of claim 42, wherein the antioxidant composition comprises at least one of coenzyme Q10, lipoic acid, vitamin, carotenoid, vitamin cofactor, mineral, polyphenol, or flavonoid,
44. The composition of claim 42 or 43, wherein the antioxidant composition
5 comprises coenzyme Q10, lipoic acid and vitamin E.
45. A composition comprising a therapeutically effective amount of an antioxidant composition, for the treatment of muscular dystrophy in a subject in need.
46. A composition comprising a therapeutically effective amount of an antioxidant composition, for the treatment of chronic muscle wasting in a subject in need.
- 10 47. A composition comprising a therapeutically effective amount of an antioxidant composition, for slowing the progression of muscular dystrophy in a subject in need.
48. A composition comprising a therapeutically effective amount of an antioxidant composition, for slowing the progression of chronic muscle wasting in a subject in need.
- 15 49. The composition of any one of claims 45-48 wherein the antioxidant composition comprises at least one of coenzyme Q10, lipoic acid, vitamin, carotenoid, vitamin cofactor, mineral, polyphenol, or flavonoid,
50. The composition of any one of claims 45-49. wherein the antioxidant composition comprises coenzyme Q10, lipoic acid and vitamin E.
- 20 51. The composition of any one of claims 45-50 wherein muscular dystrophy is dysferlin-associated muscular dystrophy, limb girdle muscular dystrophy type 2L, or Miyoshi myopathy type 3, Bethlem myopathy, calpainopathy, desmin myopathy, dysferlinopathy, myofibrillar myopathy, sarcoglycanopathie or ZASP-related myopathy.
- 25 52. The composition of any one of claims 45-51 wherein oxidative stress is reduced in skeletal muscle of the subject.

53. The composition of any one of claims 45-51 wherein skeletal muscle function of the subject is improved.
54. The composition of any one of claims 45-51 wherein the subject has a recessive mutation in the ANO5 gene.
- 5 55. The composition of any one of claims 42-54 that is formulated for oral administration.
56. The composition of any one of claims 42-55 wherein the agents are in the same composition.
57. The composition of any one of claims 42-55 wherein the agents are in
10 separate compositions.
58. The composition of any one of claims 42-55 wherein the antioxidants of the antioxidant composition are administered concurrently.
59. The composition of any one of claims 42-55 wherein the antioxidants of the antioxidant composition are administered at separate times or consecutively.
- 15 60. The composition of any one of claims 45-59 wherein the antioxidant composition is administered once daily, once weekly, twice weekly, once every two weeks, once every three weeks, monthly or once every two months.
61. Use of a recombinant AAV vector comprising 1) a nucleic acid sequence is at least 85% identical to the nucleic acid sequence of SEQ ID NO:1, 2) a nucleotide that
20 hybridizes under stringent condition to the nucleotide sequence of SEQ ID NO: 1 or 3) a fragment of nucleic acid of SEQ ID NO: 1 encoding a protein that exhibits ANO5 activity for the preparation of a medicament for treatment of muscular dystrophy in a subject in need thereof.
62. Use of a recombinant AAV vector comprising 1) a nucleic acid sequence is at least 85% identical to the nucleic acid sequence of SEQ ID NO:1, 2) a nucleotide that
25 hybridizes under stringent condition to the nucleotide sequence of SEQ ID NO: 1, or 3) a fragment of nucleic acid of SEQ ID NO: 1 encoding a protein that exhibits ANO5

activity to a subject in need thereof for the preparation of a medicament for regenerating muscle in subject in need thereof.

63. Use of a recombinant AAV vector comprising 1) a nucleic acid sequence is at least 85% identical to the nucleic acid sequence of SEQ ID NO:1, 2) a nucleotide that
5 hybridizes under stringent condition to the nucleotide sequence of SEQ ID NO: 1, or
3) a fragment of nucleic acid of SEQ ID NO: 1 encoding a protein that exhibits ANO5 activity for the preparation of a medicament for the treatment of chronic muscle wasting syndrome.

64. The use of any one of claims 61-63 wherein the recombinant AAV comprises
10 a polynucleotide sequence of SEQ ID NO: 1.

65. The use of any one of claims 61-63 wherein the recombinant AAV vector of is AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11, AAV12, AAV13 or AAV rh.74.

66. The use of any one of claims 61-65 wherein the recombinant AAV vector
15 comprises a polynucleotide operably linked to a muscle-specific control element.

67. The use of claim 66 wherein the muscle-specific control element is human skeletal actin gene element, cardiac actin gene element, myocyte-specific enhancer binding factor MEF, murine creatine kinase enhancer element, skeletal fast-twitch troponin C gene element, slow-twitch cardiac troponin C gene element, the slow-
20 twitch troponin I gene element, hypoxia-inducible nuclear factors, steroid-inducible element or glucocorticoid response element (GRE).

68. The use of claims 61-67 wherein the subject is suffering from muscular dystrophy.


69. The use of any one of claims 61-68 wherein the subject is suffering from
25 dysferlin-associated muscular dystrophy, limb girdle muscular dystrophy type 2L, Miyoshi myopathy type 3, Bethlem myopathy, calpainopathy, desmin myopathy, dysferlinopathy, myofibrillar myopathy, sarcoglycanopathie or ZASP-related myopathy.

70. The use of any one of claims 61-69 wherein the subject has a recessive mutation in the ANO5 gene.
71. The use of any one of claims 61-70 wherein the medicament is formulated for intramuscular or intravenous injection.
- 5 72. The use of any one of claims 61-71 further comprising a therapeutically effective amount of an antioxidant composition, to a subject in need thereof.
73. The use of claim 72, wherein the antioxidant composition comprises at least one of coenzyme Q10, lipoic acid, vitamin, carotenoid, vitamin cofactor, mineral, polyphenol, or flavonoid,
- 10 74. The use of claim 72 or 73, wherein the antioxidant composition comprises coenzyme Q10, lipoic acid and vitamin E.
75. Use of a therapeutically effective amount of an antioxidant composition, for the preparation of a medicament for the treatment of muscular dystrophy in a subject in need.
- 15 76. Use of a therapeutically effective amount of an antioxidant composition, , for the preparation of a medicament for the treatment of chronic muscle wasting syndrome.
77. Use of a therapeutically effective amount of an antioxidant composition, for the preparation of a medicament for slowing the progression of muscular dystrophy in
20 a subject in need.
78. Use of a therapeutically effective amount of an antioxidant composition, for the preparation of a medicament for slowing the progression of chronic muscle wasting syndrome in a subject in need.
79. The use of any one of claims 75-78, wherein the antioxidant composition
25 comprises at least one of coenzyme Q10, lipoic acid, vitamin, carotenoid, vitamin cofactor, mineral, polyphenol, or flavonoid,

80. The method of any one of claims 75-79. wherein the antioxidant composition comprises coenzyme Q10, lipoic acid and vitamin E.
81. The use of any one of claims 75-80 wherein the subject is suffering from dysferlin-associated muscular dystrophy, limb girdle muscular dystrophy type 2L, or
5 Miyoshi myopathy type 3, Bethlem myopathy, calpainopathy, desmin myopathy, dysferlinopathy, myofibrillar myopathy, sarcoglycanopathy or ZASP-related myopathy.
82. The use of any one of claims 75-81 wherein oxidative stress is reduced in skeletal muscle of the subject.
- 10 83. The use of any one of claims 75-81 wherein skeletal muscle function of the subject is improved.
84. The use of any one of claims 75-81 wherein the subject has a recessive mutation in the ANO5 gene.
85. The use of any one of claims 55-84 wherein the medicament is formulated for
15 oral administration.
86. A method of any of claims 15-30 further comprising administering a therapeutically effective amount of recombinant AAV vector comprising 1) a nucleic acid sequence that is at least 85% identical to the nucleic acid sequence of SEQ ID NO:1, 2) a nucleotide that hybridizes under stringent condition to the nucleotide
20 sequence of SEQ ID NO:1 or 3) a fragment of nucleic acid of SEQ ID NO:1 encoding a protein that exhibits ANO5 activity, in combination with a therapeutically effective amount of an antioxidant composition, to a subject in need thereof.
87. The method of claim 86, wherein the antioxidant composition comprises at least one of coenzyme Q10, lipoic acid, vitamin, carotenoid, vitamin cofactor,
25 mineral, polyphenol, or flavonoid,
88. The method of claim 86 or 87, wherein the antioxidant composition comprises coenzyme Q10, lipoic acid and vitamin E.

89. A method of any one of claims 86-88, wherein the recombinant AAV vector comprises a polynucleotide sequence of SEQ ID NO:1.
90. A method of any one of claims 86-89 wherein the recombinant AAV vector is AAV1, AAV2, AAV4, AAV5, AAV6, AAV7, AAV8, AAV9, AAV10, AAV11,
5 AAV12, AAV13 or AAV rh.74.
91. A method of any one of claims 86-89 wherein the recombinant AAV vector is administered by intramuscular or intravenous injection.
92. A method of any one of claims 86-91 wherein the antioxidant composition is administered orally.
- 10 93. The method of any one of claims 86-91, wherein the said recombinant AAV vector and antioxidant composition are in the same composition.
94. The method of any one of claims 86-92, wherein the said recombinant AAV vector and antioxidant composition are in separate compositions.
95. The method of any one of claims 86-92, wherein the said recombinant AAV
15 vector and antioxidant composition are administered concurrently.
96. The method of any one of claims 86-92 wherein the said recombinant AAV vector and antioxidant composition are administered at separate times or consecutively.
97. The method of any one of claims 86-96 wherein the said recombinant AAV
20 vector and antioxidant composition are administered once daily, once weekly, twice weekly, once every two weeks, once every three weeks, monthly or once every two months.

Figure 1







Figure 2

Figure 3







Figure 4






Figure 6

Figure 7





Figure 8



INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2016/061703

A. CLASSIFICATION OF SUBJECT MATTER IPC(8) - A61K 48/00; A61P 21/00; A61P 39/06; C07K 14/435 (2017.01) CPC - A61K 38/17; A61K 48/00; A61K 2800/522; C07K 14/4707; Y10S 514/907 (2017.01) According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC - A61K 48/00; A61P 21/00; A61P 39/06; C07K 14/435 CPC - A61K 38/17; A61K 48/00; A61K 2800/522; C07K 14/4707; Y10S 514/907 Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched USPC - 252/397; 435/375; 514/1.1 (keyword delimited) Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) PatBase, Google Patents, Google Scholar, ProQuest, PubMed Search terms used: muscular dystrophy regeneration chronic muscle wasting ANO5 antioxidant		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 2011/0082192 A1 (MILNE et al) 07 April 2011 (07.04.2011) entire document	15-19
X	EP 2 859 896 A1 (YSTEM et al) 15 April 2015 (15.04.2015) entire document	45-49, 75-79
X	US 2010/0120627 A1 (BELOUCHI et al) 13 May 2010 (13.05.2010) entire document	31-34
A	US 2014/0323956 A1 (NATIONWIDE CHILDREN'S HOSPITAL, INC) 30 October 2014 (30.10.2014) entire document	1-4, 15-19, 31-34, 45-49, 61-65, 75-79
A	US 2015/0125429 A1 (PERLINGEIRO et al) 07 May 2015 (07.05.2015) entire document	1-4, 15-19, 31-34, 45-49, 61-65, 75-79
☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 18 January 2017		Date of mailing of the international search report 02 FEB 2017
Name and mailing address of the ISA/US Mail Stop PCT, Attn: ISA/US, Commissioner for Patents P.O. Box 1450, Alexandria, VA 22313-1450 Facsimile No. 571-273-8300		Authorized officer Blaine R. Copenheaver PCT Helpdesk: 571-272-4300 PCT OSP: 571-272-7774

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US2016/061703

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☒ Claims Nos.: 5-14, 20-30, 35-44, 50-60, 66-74, 80-97
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying additional fees, this Authority did not invite payment of additional fees.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest and, where applicable, the payment of a protest fee.
- ☐ The additional search fees were accompanied by the applicant's protest but the applicable protest fee was not paid within the time limit specified in the invitation.
- ☐ No protest accompanied the payment of additional search fees.